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The emergence of antimicrobial resistance bacteria in both the medical and 
agricultural fields has become a serious problem worldwide. The use of antimicrobial 
agents in animals for prophylaxis and growth promotion favors the selection of 
antimicrobial resistance in bacteria. These resistant bacteria may subsequently 
transmit to humans through food chain or human-animal interactions. The objectives 
of this study were to characterize and determine the molecular mechanisms of 
antimicrobial resistance in Salmonella and Escherichia coli. E. coli isolates recovered 
from diseased piglets and chicken in China were characterized for the antimicrobial 
resistance phenotype and the presence of mutation in their gyrA, gyrB, parC and parE
genes. Results indicated that multiple- antimicrobial-resistant E. coli, including 
fluoroquinolone-resistant variants, are commonly present among diseased swine and 
chickens in China. DNA sequencing revealed that double gyrA mutations coupled 
with parC mutation conferred high-level resistance to fluoroquinolones. In addition,
Salmonella isolates recovered from retail meats in the United States and China were 
characterized for antimicrobial resistance genotypes and the horizontal transfer of 
resistance determinants. The antimicrobial resistance genotypes of Salmonella were 
consistent to their phenotypes. Genes conferring antimicrobial resistance in 
Salmonella are often carried on integrons and plasmids, and could be transmitted 
through conjugation. To rapidly screen for the antimicrobial-resistant and virulence 
genes from bacteria, a DNA microarray was developed to analyze the antimicrobial 
resistance and virulence genes from Salmonella and E. coli. Results indicated that 
microarrray was an effective method to rapidly screen antimicrobial resistance and 
virulence genes in Salmonella and E coli. Finally, molecular mechanisms  of 
fluoroquinolone resistance, including over-expression of efflux pumps and target gene 
mutations, were characterized among laboratory-induced and field-acquired 
fluoroquinolone-resistant Salmonella. The efflux pumps which were overexpressed in 
resistant strains were deleted and mutated gyrA and parC genes were replaced to 
determine the contribution of efflux pump and target gene mutations in 
fluoroquinolone-resistant Salmonella. When Salmonella are exposed to 
fluoroquinolone, certain efflux pumps are overexpressed in tandem with particular 
mutations in topoisomerase genes (gyrA and parC). Based on deletion mutagenesis 
studies, it appears that the most relevant genes with regards to the selection of 
fluoroquinolone resistance phenotypes among Salmonella are the AcrAB-tolC efflux 
pump and the gyrA portion of DNA gyrase gene. 
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Origins and consequence of antimicrobial resistance in food borne pathogens
The use of antimicrobials in human and animal since the discovery of penicillin in 
the late 1920s dramatically reducing the morbidity and mortality associated with 
numerous infectious diseases. This has also resulted in an unprecedented global increase 
in the incidence of clinical bacterial strains that are multiply resistant to antibiotics. 
Bacterial antimicrobial resistance in both the medical and agricultural fields has become a 
serious problem worldwide (125). Antibiotic resistant strains of bacteria are an increasing 
threat to animal and human health, with resistance mechanisms having been identified 
and described for all known antimicrobials currently available for clinical use. The 
administration of therapeutic and sub-therapeutic antimicrobials to animals caused the 
emergence and dissemination of multiple-antibiotic-resistant zoonotic bacterial 
pathogens, which currently has become a increased public and scientific interest (155, 
191). Although there is still lack of evidences of the use of antimicrobials in animals on 
the development and dissemination of antibiotic resistance among human bacterial 
pathogens, research has linked the use of antibiotics in agriculture to the emergence of 
antibiotic-resistant foodborne pathogens (155, 191, 230). To date, bacterial pathogens of 
animal and human origin are becoming increasingly resistant to most frontline 
antimicrobials, including expanded-spectrum cephalosporins, aminoglycosides, and 
fluoroquinolones. The increasing incidence of antimicrobial-resistant bacterial pathogens 
has severe implications for the future treatment and prevention of infectious diseases in 
animals and humans. 
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Antimicrobial use in animal husbandry 
There are three ways in which substances exhibiting antimicrobial activity are used 
in animals: for therapy, prophylaxis, and growth promotion (187). Therapeutic use of 
antimicrobial agents is intended to cure an existing bacterial infection. In food-producing 
animals, antimicrobials are given for group treatment because individual animal 
treatment is often impractical. Metaphylaxis is the application of antimicrobials to a 
group of animals when signs of disease are present in some animals to prevent spread of 
the infections. Early medication to the entire animal group may reduce the numbers of 
sick and/or dead animals and also may decrease the amount of antimicrobial agents 
needed to treat large numbers of the symptomatically ill population, consequently, 
reducing treatment costs. 
In contrast to therapeutic use of antimicrobials, prophylaxis is a solely preventive 
measure which should be used with discretion. In the pork- and beef-producing industry, 
the antimicrobials were prophylactic used at the key time, such as weaning, or mixing of 
animals from different herds. Although animals usually do not exhibit symptoms of a 
disease at such time, it can be expected that the animals will become infected shortly 
thereafter based on experience. Antimicrobial prophylaxis at these times is essential in 
many piggeries and byres because frequently-occurring respiratory and enteric disease in 
cattle and pigs cannot be effectively controlled without prophylactic use of antimicrobials 
(46, 99). Although prophylactic herd treatment is criticized for its role on the selection of 
resistance among pathogenic bacteria (211), antimicrobial prophylaxis at these key 
periods for disease incidence is an unavoidable measure in the current pork and beef 
producing systems.
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Even more critically assessed is the use of antimicrobial agents for growth 
promotion in food animals (211). The mode of action of antimicrobial growth promoters 
is not fully understood. However, the main effects are believed to be a reduction of the 
growth of bacteria in the intestinal tract and thereby less microbial degradation of useful 
nutrients, and the prevention of infections with pathogenic bacteria (3). Numerous studies 
on the economic benefit of the use of antimicrobial growth promoters have been 
performed. In general, an improvement in growth rate and feed utilization has been 
observed. 
The association between the use of antimicrobials in food animals and the occurrence of 
antimicrobial-resistant bacteria
More than half of all antimicrobials used are associated with the production of food 
animals and a substantial portion of this is used for growth promotion and prophylactic 
purposes (131, 142). Thus, bacterial species related to food animals are exposed to a 
substantial and in many cases constant, selective pressure. This selective pressure favors 
the emergence of antimicrobial resistance in zoonotic pathogens such as Salmonella, 
Campylobacter, Yersinia, Listeria and diarrheagenic E. coli, which are frequently 
harbored in the animal intestinal tract. It also favors the selection of antimicrobial 
resistance genes in non-pathogenic bacteria (2, 3), which later may transfer the acquired 
resistance to different pathogenic bacterial species. Knowledge regarding associations 
between use of antimicrobial agents and occurrence of resistance is in many cases based 
on experience of changes in occurrence of resistance in relation to introduction of new 
agents.
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There are some good examples of the introduction of antimicrobials for animal use 
and the emergence of resistant bacteria. In the United States, the increase in the 
occurrence of fluoroquinolone-resistant Campylobacter and E. coli has been observed 
after the introduction of fluoroquinolones into veterinary medicine in 1995 and 1996 
(http://www.hhs.gov/news/press/1995pres/950818b.html). Because of the emergence of 
fluoroquinolone resistance in Campylobacte, the FDA proposed withdrawing the 
approval of fluoroquinolones for all poultry 2002. In Germany, an increase in the 
occurrence of fluoroquinolone resistance among S. Typhimurium DT204 occurred after 
the introduction of enrofloxacin for veterinary use in 1989 (87). Most recently, in the UK 
substantial increases in resistance to fluoroquinolones in S. Hadar and S. Virchow and 
also in multiple-resistant S. Typhimurium DT104 have followed the licensing for 
veterinary use of enrofloxacin in 1993 and danofloxacin in 1996 (204).  
Another example is the use of aminoglycosides in Europe. After the introduction of 
the aminoglycoside antibiotic apramycin for veterinary use at the begining of the 1980s, 
resistance to apramycin emerged among E. coli isolates found in cattle and pigs in France 
and the UK. Although apramycin has never been used for treatment of infections in 
humans, the gene aac(3)-IV encoding resistance to apramycin also conferred resistance to 
gentamicin, which was widely used in humans (123). The same resistance gene and 
plasmid have since been found in Salmonella from animals and in human clinical E. coli
isolates (123). These observations strongly suggest that this resistance gene primarily 
emerged among food animals because of the selection by use of apramycin in food 
animals, and was then transmitted to humans. 
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We characterized the phenotypes and genotypes of Salmonella isolated from retail 
meats in the US and China (33). Nineteen percent of the Salmonella isolates from the US 
were resistant or intermediately susceptible to ceftriaxone and harbored the blaCMY-2 gene. 
Conversely, each of the Salmonella isolates from China was susceptible to ceftriaxone 
(and other cephalosporins), and none harbored blaCMY-2. A possible explanation for this 
observation is that ceftriaxone-resistant Salmonella in meats have arisen due to cross-
resistance between ceftriaxone and ceftiofur, a cephalosporin used in food animals (205, 
234). Ceftiofur, the only cephalosporin approved for therapeutic use in cattle, has been 
approved for use in the US since 1988 and for use in China in 2002 
(www.agri.gov.cn/blgg/t20021219_36976.htm). Quinolones and fluoroquinolones have 
been used in veterinary medicine in China since the 1980s. In contrast, they were not 
approved for therapeutic use in animals in the US until 1995. The differences in 
fluoroquinolone susceptibility between the US and China isolates likely reflect the 
different approval dates in the two countries.  Thirty-two of the Salmonella isolates from 
China were resistant to nalidixic acid and displayed increased minimum inhibitory 
concentration (MIC) for ciprofloxacin, while all of the isolates from the US were 
susceptible to these drugs.  
Potential mechanisms of increased disease in humans from antimicrobial resistance in 
food animals
Simply showing that a growing proportion of pathogens and commensal organisms 
isolated from food animals are resistant to antimicrobial agents is not enough to prove a 
human health hazard. Rather, it must be demonstrated that as a result of such 
antimicrobial resistance infections are more numerous or are more severe or are less 
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easily treated than would be the case otherwise. There are some potential mechanisms of 
increased disease in humans from antimicrobial resistance in food animals, which are 
discussed in the following paragraphs (14). 
First, exposure of food animals to antimicrobial agents can not only select 
antimicrobial-resistant pathogens, but also might lead to increased colonization of the 
animals by antimicrobial-resistant pathogens. This is because treatment with 
antimicrobial agents often results in the reduction of various components of the 
commensal flora, which normally exerts a protective effect against colonization and 
infection of exogenous organisms (207). This increase in the number of pathogens in 
food animals could lead to an increase in the burden of pathogens in the environment and 
in the food chain up to human consumers. Furthermore, as in humans, most of these 
pathogens would presumably be resistant to antimicrobial agents.
Second, antimicrobial resistance arising in food animals could involve not just 
obvious pathogens but relatively nonpathogenic bacteria such as generic E. coli or 
entercocci. These organisms could become reservoirs of mobile antimicrobial resistance 
elements that could colonize humans via food or environmental exposure. These 
resistance elements could then be transferred to pathogens in the gut (212). 
Third, infection by antimicrobial-resistant microorganisms might have a worse 
outcome due to ineffective initial treatment, the need to use less desirable treatment 
options, or both. The initial empiric treatment choice might be an antimicrobial agent to 
which the pathogen is resistant, leading to a delay in effective therapy (154). Effective 
agents might be more toxic, more expensive, or more difficult to administer than 
traditional choices.
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Last, there might be genetic linkage of resistance traits and virulence factors, 
resulting in increased virulence of resistant strains (48, 60, 194, 219). An increase in 
virulence would arise not directly from an antimicrobial resistance mechanism itself but 
from linkage of resistance genes to other virulence genes which are maintained by drug 
use. Co-transfer of resistant traits and virulence genes could make drug-resistant 
pathogenic strains intrinsically more virulent than drug-susceptible strains. In addition, it 
is possible that bacterial adaptation to high concentrations of antimicrobials can somehow 
enable them to better survive in the host system. For instance, antimicrobial-resistant 
bacteria may have increased resistance to antibacterial peptides or bile salts secreted by 
the host system. 
Antimicrobial resistance in Salmonella and Commensal bacteria
The antimicrobial resistance in bacteria is increasing in recent years. At least 17 
classes of antimicrobial agents are approved for growth promotion and feed efficiency in 
the US, including: tetracyclines, penicillins, macrolides, lincomycin (an analog of 
clindamycin), and virginiamycin (an analog of quinupristin/dalfopristin). The use of 
antimicrobial agents in food animals creates a selective pressure for the emergence and 
dissemination of antimicrobial-resistant bacteria including animal pathogens, humans 
pathogens which have food animal reservoirs, and other bacteria which are present in 
food animals (43, 110, 211). The National Antimicrobial Resistance Monitoring System 
(NARMS) was launched in 1996 to monitor antimicrobial resistance in foodborne enteric 
pathogens. 50 state and 4 local public health laboratories currently participate in NARMS 
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and the antimicrobial resistance of human enteric bacteria, including Campylobacter, 
Salmonella, Escherichia coli O157, and Shigella were monitored. 
Antimicrobial resistance in Salmonella
Salmonella was the first organism that was monitored for antimicrobial resistance 
by NARMS. From the past five NARMS annual reports, the highest prevalence of 
resistance in Salmonella were tetracycline, sulfamethoxazole, streptomycin, and 
ampicillin, ranging from 15~25%. The emergence of multidrug-resistant S. Typhimurium 
DT104 in the US and UK, which is resistant to ampicillin, chloramphenicol, 
streptomycin, sulfonamides, and tetracycline (ACSSuT), constitutes a considerable 
portion of the Salmonella isolates analyzed in NARMS. The prevalence of S. 
Typhimurium isolates with the five-drug pattern of resistance increased from 0.6% in 
1979-1980 to 34% in 1996 (163). This strain remains common; among S. Typhimurium 
isolates submitted to NARMS, the prevalence of the ACSSuT resistance pattern was 29% 
in 2001 (164).
In recent years, the portion of Salmonella which is resistant to clinically important 
drugs such as fluoroquinolones (e.g., ciprofloxacin) and third-generation cephalosporins 
(e.g., ceftriaxone) is increasing. Antimicrobial agents are commonly used empirically for 
treatment of patients with Salmonella infections and may be life-saving for persons with 
invasive infections. Fluoroquinolones are the most commonly used antimicrobial agent 
for the treatment of invasive Salmonella infections in adults (9). Although few non-Typhi 
Salmonella isolates in NARMS from 1996-2001 were resistant to fluoroquinolones (MIC 
> 4 µg/ml), 1% of isolates in 2001 had a decreased susceptibility to fluoroquinolones 
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(MIC >0.25 µg/ml), an increase from 0.4% in 1996(163) . Patients infected with 
Salmonella strains with a decreased susceptibility to fluoroquinolones may respond 
poorly to treatment with fluoroquinolones and have been associated with apparent 
treatment failures (47, 133). Because of this, it has been proposed that the resistance 
breakpoint for ciprofloxacin be lowered. 
Third-generation cephalosporins, such as ceftriaxone, are commonly used for 
treatment of invasive Salmonella infections in children because of their 
pharmacodynamic properties and low prevalence of resistance to these agents. There is 
therefore concern about the potential emergence of ceftriaxone-resistant Salmonella. The 
first reported case of domestically acquired ceftriaxone-resistant Salmonella was in a 12-
year-old child in Nebraska (59). Investigation by public health officials revealed that the 
Salmonella strain most likely came from cattle herds. The use of ceftiofur or other 
antibiotics likely selected for and maintained the ceftriaxone-resistant determinant within 
the intestinal flora of the involved herds, after which the ceftriaxone-resistant strains was 
transmitted to the child through his father, a veterinarian. 
The Nebraska child’s ceftriaxone-resistant infection was not an isolated event. The 
percentage of non-Typhi Salmonella isolates in NARMS resistant to ceftriaxone 
increased 20 fold from 0.1% in 1996 to 2% in 2001(164). When patients from whom 
isolates were received in 1996-1998 were interviewed, few reported international travel, 
suggesting that most infections were domestically acquired (54). Furthermore, 
ceftriaxone resistance in most domestically acquired infections, including the infection in 
the child in Nebraska, is due to a unique AmpC-type resistance gene (blaCMY-2), which 
resides on a plasmid (54, 59). A 1999 study at the University of Iowa found multidrug-
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resistant, cephalosporin-resistant bovine, porcine and humans Salmonella isolates from 
the same geographic region. All humans and animal resistant isolates encoded a blaCMY-2 
AmpC-like gene (233). Interestingly, a study conducted in our lab indicated that 
ceftriaxone-resistant Salmonella carrying a blaCMY-2 coded on a conjugative plasmid was 
prevalent in ground meats in the greater Washington DC area (33, 230). The finding of a 
similar molecular mechanism of resistance among different Salmonella strains supports 
the hypothesis of dissemination of a resistance determinant and the transmission of 
antimicrobial-resistant Salmonella from animals to humans through the food supply (54).
Another multidrug-resistant Salmonella that has emerged recently in the United
States is MDR-AmpC Salmonella Newport. These multidrug-resistant strains are resistant 
to ampicillin, chloramphenicol, streptomycin, sulfamethoxazle, and tetracycline 
(ACSSuT), and have apparently acquired the blaCMY-2AmpC-like gene
conferring additional resistance to cephalothin, amoxicillin-clavulanic acid, cefotoxin,
and ceftiofur (243). Of S. Newport isolates submitted to NARMS in 2001, a
remarkable 25% were MDR-AmpC S. Newport (164). The MDR-AmpC S. Newport has 
been detected in very high frequency in meat products and food animals. Recently, we 
also isolated MDR-AmpC S. Newport from organic chicken samples. 
Antimicrobial resistance in commensal bacteria
Pathogenic bacteria, such as Campylobacter and Salmonella, are not the only
concern when considering antimicrobial resistance in bacteria with food animal
reservoirs. Commensal bacteria, which are naturally occurring host flora, constitute an
enormous potential reservoir of resistance genes for pathogenic bacteria. The prevalence 
11
of antibiotic resistance in the commensal bacteria of humans and animals is considered to 
be a good indicator of the selective pressure of antibiotic usage and reflects the potential 
for resistance in future infections (92, 108). Most resistant bacteria have mobile genetic 
elements such R-plasmids and transposons. As the reservoir of resistant commensal 
bacteria increases, the plasmid reservoir becomes larger and enables more frequent 
transfer of resistance to pathogenic bacteria including Salmonella and Shigella. E coli, 
which is the predominant isolate of aerobic fecal flora in humans and most animals, has 
demonstrated its ability to transfer resistance genes to other species, including pathogenic 
bacteria (92, 146, 190, 202, 235). 
Quinupristin/dalfopristin was approved for use in humans in 1999 for treatment of 
vancomycin-resistant Enterococcus faecium infections. Virginiamycin, an analog of 
quinupristin/dalfopristin, has been used as a growth promoter in food animals in the 
United States since 1974. A study conducted by the CDC in 1998-1999, before the 
approval of Quinupristin/dalfopristin use in humans, found quinupristin/dalfopristin-
resistant E. faecium on 58% of chickens purchased in grocery stores from four different 
states. Additionally, quinupristin/dalfopristin-resistant E. faecium was found in 1% of the 
stools from non-hospitalized people who submitted a stool specimen to clinical 
laboratories (126). Similar data in Europe led the European Union to ban the 
subtherapeutic use of virginiamycin in food animals in 1998 (225). These findings 
suggest virginiamycin use in food animals has created a large reservoir of 
quinupristin/dalfopristin-resistant E. faecium. The high carriage of 
quinupristin/dalfopristin-resistant E. faecium on chickens in grocery stores, and the 
frequent handling of chicken from grocery stores by consumers, suggests that humans are 
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commonly exposed to these resistant bacteria. The use of quinupristin/dalfopristin in 
humans for the treatment of vancomycin-resistant E. faecium and other serious infections 
may contribute additional selective pressure leading to an increased prevalence of 
quinupristin/dalfopristin resistance in humans.
Recent studies have also shown an emerging resistance in E. coli to 
fluoroquinolones and third-generation cephalosporins. A study by Garau et al., 
demonstrated an increase in quinolone resistance among E. coli isolates in Spain from 9% 
to 17% over the course of five years. This study also showed a high prevalence of 
quinolone-resistant E. coli in healthy children and adults (26% and 24% respectively) 
which could not be explained by previous use of quinolones. Animal testing from 
slaughterhouses in the area found a high rate of quinolone-resistant E. coli in swine and 
chickens (45% and 90%, respectively) (64). Winokur et al., found 16% of clinical E. coli
isolates from cattle and swine and 1% of clinical human E. coli isolates collected in Iowa 
to be resistant to extended spectrum cephalosporins. This study also identified identical 
blaCMY-2 genes in resistant isolates from both humans and animals suggesting transfer of 
the resistance gene between food animals and humans (235). The frequency of 
fluoroquinolone resistance in animal E. coli isolates from developing countries is much 
higher than the clinical human isolates. Around 90% of E. coli isolates from chicken and 
50% of E. coli from swine have been reported to be resistant to fluoroquinolones in Spain 
and China (178, 221). 
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Mechanisms of antimicrobial action and resistance
An ideal antimicrobial drug exhibits selective toxicity. This term implies that the 
drug is harmful to a parasite without being harmful to the host. The most successful 
antimicrobial agents are those whose targets are anatomic structures or biosynthetic 
functions unique to microorganisms. Resistance to antimicrobial agents in bacteria is 
mediated by several mechanisms, including 1) changes of bacterial cell wall 
permeability, 2) energy-dependent removal of antimicrobial agents via membrane bound 
efflux pumps, 3) modification of the site of drug action, and 4) destruction or inactivation 
of antimicrobial agents (13, 186). The antimicrobial-resistant phenotypes is gained from 
extra-chromosomal genes that may confer resistance to an entire antimicrobial class. 
Most of these resistance genes are associated with transferable plasmids, on which may 
be other DNA mobile elements, such as transposons and integrons (94, 182, 183). These 
DNA mobile elements played an important role on dissemination of resistance genes 
among different bacteria. The mechanisms of action and resistance of six major 
categories of antimicrobial agents are described below. 
β-Lactams
β-Lactams represent groups of antibiotics that include penicillins, cephalosporins, 
monobactams and carbapenems. These groups of drugs inhibit a number of bacterial 
enzymes, namely, penicillin-binding proteins (PBPs), that are essential for peptidoglycan 
synthesis, thereby interfering with synthesis of petidoglycan of the cell wall (223). Of the 
various mechanisms of acquired resistance to β-lactam antibiotics, resistance due to 
production of β-lactamase by the cell is the most prevalent (25, 114). β-Lactamase 
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included a family of enzymes with tremendous diversity. The blaTEM-1 and blaSHV-1, which 
efficiently hydrolyze penicillins and narrow-spectrum cephalosporins but poorly 
hydrolyzes extended-spectrum cephalosporins, are the most prevalent and most common 
in Gram negative bacteria (193). Recently, a plasmid-mediated AmpC β-lactamase 
blaCMY-2, which causes resistance to extended spectrum β-lactams (ESBLs) including 
ceftriaxone, has emerged in S. Typhimurium (54, 65, 102). The plasmid-mediated blaCMY-
2 was also detected in the recently emergent MDR-AmpC S. Newport (77). In addition, 
alterations in the PBPs, acquisition of a novel PBP insensitive to β-lactams, changes in 
the outer membrane proteins of Gram-negative organisms, and active efflux which 
prevent these compounds from reaching their targets can also confer resistance.
Aminoglycosides
Aminoglycosides are a class of drugs which inhibit bacterial protein synthesis by 
binding irreversibly to the bacterial 30S ribosome subunits. The aminoglycoside-bound 
bacterial ribosome is unavailable for translation of mRNA during protein synthesis 
thereby causing bactericidal effects (107). The most common mechanism of 
aminoglycoside resistance is antibiotic inactivation by plasmid-and transposon- encoded 
modifying enzymes (189). There are three classes of aminoglycoside-modifying 
enzymes: acetyltransferases (AAC), adenylytransferases (ANT), and phosphotransferases 
(APH). AAC enzymes acetylate amino groups, whereas ANT and APH enzymes 
adenlylate and phosphorylate hydroxyl groups, respectively. An ANT enzyme, AadA, 
which is encoded in integrons is commonly detected in streptomycin-resistant Gram 
negative bacteria. In addition, the resistance also is caused by the decreased antibiotic 
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uptake by outer membrane proteins and the mutation of ribosomal protein S12, which is 
the target of aminoglycoside antibiotics (96).
Phenicols
Phenicols include chloramphenicol and florfenicol. They inhibit protein synthesis 
by binding reversibly to the peptidyltransferase component of the 50S ribosomal subunit 
thus preventing the transpeptidation process of peptide chain elongation (45). Only 
chloramphenicol is available for clinical use in the United States. Chloramphenicol 
resistance in bacteria most commonly results from acquisition of plasmids encoding 
chloramphenicol acetyltransferases (CAT), which enzymatically inactivate the drug. In 
Gram negative bacteria, three types of CAT enzymes (types I, II, III) have been identified 
(151). In addition to enzyme resistance is also due to the decreased outer membrane 
permeability and acquisition of extra chromosomal efflux pumps (20). cmlA is a major 
facility family transporter based on the amino acid sequence analysis. cmlA can also 
result in reduced expression of two outer membrane proteins (OmpA and OmpC) and 
decreased chloramphenicol uptake. Recently, a new gene, flo, which shares 65% 
homology to cmlA, was found to confer  resistance to both chloramphenicol and 
florfenicol (101, 228).
Sulfonamides and Trimethoprim
Sulfonamides were the first effective systemic antimicrobial agents used in the 
United States during the 1930s. They work by competitively inhibiting bacterial 
modification of para-aminobenzoic acid into dihydrofolate. Trimethoprim is a pyrimidine 
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analog that inhibits the enzyme dihydrofolate reductase(DHFA), thus interfering with 
folic acid metabolism. This sequential inhibition of folate metabolism ultimately prevents 
the synthesis of bacterial DNA (176). The widespread high-level resistance to 
trimethoprim is likely due to the acquisition of exogenous DNA that specifies a 
supplementary DHFR which is less sensitive than the chromosomal enzyme to inhibition 
by trimethoprim (8). To date, at least 16 different DHFRs have been characterized in 
Gram-negative bacteria. Type I DHFR is most commonly detected in Gram negative 
bacterial and normally carried by integrons (198). Resistance to sulfonamide is 
commonly due to acquisition of plasmids that encode a drug-resistant dihydropteroate 
synthase (DHPS). Two types (type I and II) of resistant DHPS, encoded by the sulI and 
sulII genes, respectively, have been identified in Gram-negative organisms (167, 197). 
The sulI gene is often linked to other resistance genes and is located in conserved 
segments of integrons in Tn21-like elements carried by large conjugative plasmids. The 
sulII gene is frequently linked genetically to a streptomycin resistance gene on broad-
host-range plasmids and on small nonconjugative plasmids. 
Tetracycline
The tetracyclines act by inhibiting protein synthesis. They enter bacteria by an 
energy-dependent process and bind reversibly to the 30S ribosomal subunits of the 
bacteria. This process blocks the access of aminoacyl-tRNA to the RNA-ribosome 
complex, preventing bacterial polypeptide synthesis (37). Tetracycline resistance is the 
most common antibiotic resistance encountered in nature. Although it can result from 
chromosomal mutations affecting outer membrane permeability (44), more commonly it 
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results from acquisition of exogenous DNA encoding proteins involved in active efflux of 
tetracycline or in protection of the ribosome (246) (115).
In Gram-negative bacteria, six classes of tet efflux pumps including TetA, TetB, 
TteC, TetD, TetE, TetG, are of clinical importance. These efflux pumps use an antiport 
mechanism of transport involving the exchange of a proton for tetracycline-cation 
complex (115). Another mechanism of tetracycline resistance is ribosome protection. 
Modification of tRNA has been suggested to interfere with ribosomal protection, but its 
precise role remains to be determined. At least five classes of ribosomal proteins, which 
can interact with ribosomes such that the protein is unaffected by the presence of 
antibiotics, have been characterized. tetM is widely disseminated and is found in many 
Gram-positive and Gram-negative bacteria. Like some other antimicrobial agents, 
tetracycline resistance is also mediated by decreased membrane permeation and active 
efflux pumps (246). 
Quinolones/ Fluoroquinolones
Quinolones belong to a group of potent antibiotics biochemically related to 
nalidixic acid, which were developed initially as a urinary antiseptic. Newer quinolones, 
also known as fluoroquinolones, have been synthesized by adding a fluorine atom 
attached to the nucleus at position 6. The primary target of quinolones is DNA gyrase, an 
enzyme essential for DNA replication (82, 89, 237). Their therapeutic index stems from 
the fact that the clinically useful fluoroquinolones inhibit bacterial DNA gyrase at 
concentrations far below those required to inhibit mammalian topoisomerases. The 
mechanisms of fluoroquinolone resistance include target gene mutation and removal 
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fluoroquinolones by efflux pumps. These mechanisms will be discussed in detail in the 
following paragraphs(32, 41, 158, 213).  
Mechanisms of fluoroquinolone resistance in E. coli and Salmonella
Bacterial resistance to fluoroquinolones is usually mediated by removing drug by 
active efflux pumps and development of mutations in fluoroquinolone action targets 
(bacterial gyrase and topoisomerase IV). It was suggested that enhancing expression of 
efflux pumps occurs as a first step, allowing the bacteria to survive so that mutations can 
accumulate in genes encoding target proteins to cause higher level resistance (157). Little 
is know about the fluoroquinolone resistance in Salmonella so far because the reports of 
fluoroquinolone-resistant cases are rare. However, the resistance to fluoroquinolones in 
Salmonella is increasing (29, 34, 72, 119, 136, 156, 164). This represents substantial risks 
to human health. Studies are needed to determine the molecular mechanisms of 
fluoroquinolone resistance in Salmonella because understanding the mechanisms of 
antibiotic resistance should enable us in the future to develop intervention strategies to 
reduce or arrest the progression of antibiotic resistance and to identify new drug target.
Quinolones and fluoroquinolones
Fluoroquinolones are synthetic antibacterial agents which are basically composed 
of an 4-oxo-1,8-naphthyridin-3-carboxylic acid nucleus. For two decades, they have 
become from a relatively small group of drugs used predominantly for urinary track 
infections (UTIs) to a class that had a worldwide sale of $3.04 billion in 1997. A number 
of characteristics have led to the wide use of fluoroquinolones including rapid 
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bactericidal effects against most susceptible organisms, extremely good penetration into 
tissues and mammalian cells, and broad-spectrum activity to most of Gram-negative and 
Gram-positive bacteria (10). 
The first marketed quinolone, nalidixic acid (1st generation quinolone, patented in 
1962), has only modest antimicrobial activity against Gram-negative bacteria and lower 
oral absorption. High urinary concentration makes it suitable for UTIs. Soon after its 
introduction into widespread clinical use, it was found that a number of organisms could 
rapidly develop resistance to nalidixic acid. The real breakthrough in fluoroquinolones 
came with discovery of 2nd generation quinolon norfloxacin to which a 6-fluorinated 
compound with a piperazing ring at position 7 were added to quinolones. Although 
norfloxacin has activity against a broad spectrum of Gram-negative and has Gram-
positive activity, the combination of its pharmacokinetic profile and activity are still not 
adequate for systemic use. One of the most successful and widely used compounds of the 
class, ciprofloxacin (2nd generation quinolone, patented in 1981) was marketed in 1986 
and since then the value of the fluoroquinolones for the treatment of a wide range of 
infections has become widely recognized. The advantages of this compound are its 
broad-spectrum activity including Gram-positive as well as Gram-negative pathogens and 
its good absorption in the gastrointestinal track, providing adequate blood levels to allow 
its use in systemic infections. However, resistance to ciprofloxacin in bacteria is 
increasing, especially in Gram-positive bacteria like Staphylococcus. Recently developed 
fluoroquinolones including levofloxacin and gemifloxacin (3rd and 4th generation 
quinolones, respectively), have improved activity against Gram-positive, anaerobes and 
same activity against Gram-negative as ciprofloxacin. These compounds do not select for 
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resistance at such a high rate as ciprofloxacin and are active against ciprofloxacin-
resistant bacteria (10). Several compounds in these classes have been approved for 
clinical use by FDA in 2002. Growth in the market for fluoroquinolones is likely to 
continue. However, prudent use of these compounds is necessary to prevent the rapid 
spread of resistance in bacteria.
Interaction of fluoroquinolones with bacterial gyrase and topoisomerase IV 
Fluoroquinolones are potent antibacterial agents that target two related enzymes, 
DNA gyrase and DNA topoisomerase IV (109). Gyrase, which is composed of two 
subunits, GyrA and GyrB, is responsible for introducing negative supercoils into DNA 
and for relieving torsional stress expected to accumulate ahead of transcription and 
replication complexes. Topoisomerase IV, which is composed of two subunits, ParC and 
ParE, provides a potent decatenating (unlinking) activity to separate two sets of replicated 
DNAs. Fluoroquinolones do not simply eliminate enzyme function; they actively kill 
cells by trapping these two enzymes on DNA as a drug/enzyme/DNA complex in which 
double-stranded breaks are held together by protein (97, 98). Briefly, when 
fluoroquinolones bind to an enzyme/DNA complex, the conformation of the protein is 
changed and the ATPase activity is altered, which results in a distortion in DNA. The 
distortion causes the break of double-strand DNA. When the DNA is released from 
cleaved complex, the break of the chromosome leads to cell death. In gram negative 
bacteria, the gyrase is the primary target of quinolone drugs and mutations in gyrase 
always happen before those in toposiomerase. The topoisomerase is the secondary target 
and the mutations in topoisomerase IV always happen after the gyrase mutations. 
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Fluoroquinolone-resistant mutations of GyrA reduce quinolone binding to the enzyme-
DNA complex. The same might be true for mutation in ParC (53).   
Quinolone resistance due to altered gyrase and topoisomerase IV
The gene that confers nalidixic acid resistance in early studies became known as 
gyrA. When coexpressed with a wild type (sensitive) gyrA allele, resistance is recessive 
by the dominant presence of wild type allele (79, 192). Similar experiments have been 
done in E. coli to demonstrate the role of parC mutations in clinical isolates (84, 105). 
Sequence analysis of DNA from several bacterial species shows that resistance mutations 
tend to alter amino acids near the putative active site in the GyrA protein.  This region, 
extending between amino acids 67 and 106, is called the quinolone resistance 
determining region (QRDR). A similar region is believed to exist in the ParC protein. 
Within GyrA of E. coli, mutations of two codons, serine 83 and aspartic acid 87, are most 
commonly detected. A single mutation in either site confers resistance to nalidixic acid 
(226, 242). When both sites are mutated, the level of resistance to nalidixic acid can be 
three or fourfold higher than that of a single mutations and the cell become resistant to 
ciprofloxacin (12, 201, 208, 216). Mutations in ParC are only detected in GyrA mutants 
and always with high fluoroquinolone resistance. Topoisomerase IV mutations do not by 
themselves confer resistance. It is suggested  that GyrA is the primary target in E. coli 
and firstly mutated under fluoroquinolone selective pressure, whereas ParC is as the 
secondary target and secondly mutated under higher fluoroquinolone selection pressure. 
Mutations in GyrB could be found in both high and low quinolone resistance isolates. 
Clinical GyrB mutations are analyzed in two specific sites, Asp426 and Lys 447, in E. 
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coli (240). Recent crystal structure of yeast topoisomerase IV demonstrated a quinolone-
binding pocket around the active site for DNA cleavage. GyrB belongs to part of the 
quinolone-binding pocket. The quinolone resistance mutations in GyrB exist at the distant 
sites of the gene (83). The homologous gene for topoisomerase IV, ParE, can also display 
resistance mutations. 
In Salmonella, single mutations in GyrA, Ser83 or Asp87, have been identified in 
quinolone-resistant isolates recovered from humans and animals (78, 159, 172). 
Mutations in both Ser83 and Asp87 in GyrA are detected in ciprofloxacin-resistant 
Salmonella isolates from humans and animals (34, 85, 156). Mutations in GyrB have also 
been shown, with a substitution of Ser464Tyr revealed in one clinical isolate. A mutation 
in ParC (Ser80Arg) was only reported recently. The role of ParC mutation in 
fluoruoquinolone-resistant Salmonella was not clear because 1) the ParC mutation was 
not consistently associated with high fluoroquinolone-resistant Salmonella and was only 
reported recently, and 2) there is no genetic evidence to link the ParC mutation to 
fluoroquinolone resistance in Salmonella. In addition, a novel ParC mutation (Tyr57Ser) 
was reported in fluoroquinolone-susceptible (ciprofloxacin MIC < 0.06µg/ml) Salmonella
isolated from Hong Kong (112). A ParE mutation (Ser458Pro) was reported recently in 
ciprofloxacin-resistant (ciprofloxacin MIC ranges from 16 to 64 µg/ml) Salmonella
isolates with additional double GyrA mutations and one ParC mutation (112).
Fluoroquinolone resistance and efflux pumps 
         The Gram-negative cell wall consists of an outer membrane, periplasm, and a 
cytoplasmic membrane. The outer membrane contains pore-forming proteins (porins) 
such as OmpF and OmpC that allow solutes, including antibiotics, into the cell(156). 
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Efflux pumps are transport proteins involved in the extrusion of toxic substrates 
(including antibiotics) from within cells into the external environment. In the prokaryotic 
kingdom there are five major superfamilies of active drug efflux pump transporters: ATP-
binding cassette (ABC), major facilitator superfamily (MFS), small multidrug resistance 
(SMR), multi antimicrobial resistance (MAR), resistance nodulation division (RND). 
Genome sequence analyses of prokaryotic microorganisms with available complete 
sequence revealed that about 5~10% of all bacterial genes are involved in transport, and 
that a large proportion of these genes encode efflux pumps. Antibiotic efflux pumps 
appear a major component of microbial resistance to many classes of antimicrobial agents 
(210). In many cases, efflux pump genes are within an operon, with a regulatory gene 
controlling their expression. Increased expression of efflux pump genes is associated with 
the resistance to substrates including antibiotics. Overexpression of efflux pump genes 
can result from mutations within local repressor genes or may result from activation of a 
regulon regulated by a global transcriptional regulator such as MarA or SoxS. For at least 
four of antibiotics, namely tetracycline, macrolide, chloramphenicol, and 
fluoroquinolone, antibiotic efflux pumps appear to confer medium or high level of 
antibiotic resistance, defeating medically applicable treatments of the corresponding 
infections with these antimicrobial agents (16, 111, 147, 161, 166).
 Efflux pumps that contribute to antibiotic resistance have been described from a number 
of clinically important bacteria other than Salmonella, including Campylobacter jejuni
(CmeABC ), E. coli (AcrAB-TolC, AcrEF-TolC, EmrB, EmrD), Pseudomonas 
aeruginosa (MexAB-OprM, MexCD-OprJ, MexEF-OprN and MexXY-OprM), 
Strepotococcus pneumoniae (PmrA), Staphylococcus aureus (NorA) (156). An antibiotic 
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efflux pump has been described in Salmonella is AcrAB-TolC system where AcrB is an 
efflux protein in the cytoplasmic membrane and AcrA is an accessory protein, linking 
AcrB with the outer membrane protein TolC (68, 160) (Fig 2). Overexpression of 
AcrAB-tolC is mediated by the overexpression of transcriptional activators MarA and 
SoxS, which are regulated by MarR and SoxR proteins (6, 169) and by repressor (AcrR) 
mutations (116). The overexpression of MarA and SoxS down regulates OmpF, an outer 
membrane pore forming protein. The net result is that the expression of OmpF is reduced 
and less drugs is able to enter the cell, that the expression of AcrAB is increased, 
enhancing efflux from cell. The acrAB-tolC efflux pump plays an important role in 
fluoruoquinolone resistance in Salmonella (16, 30). Other efflux pumps have not yet been 
studied in Salmonella. However, Piddock, L. J et al (160) reported that clinical 
Salmonella isolates that accumulated less ciprofloxacin than pretherapy isolates, did not 
show any increased expression of AcrAB, MarA, SoxS, suggesting another efflux pumps
may contribute to the removal of ciprofloxacin in these Salmonella isolates. 
Clinical consequence of fluoroquinolone-resistant Salmonella
Salmonellosis is an important public health problem in the United States(128) . Most 
human Salmonella infections result in a self-limiting gactrointestinal illness characterized 
by diarrhea, fever, and abdominal cramps. However Salmonella infections that spread to 
the bloodstream, meningeal linings of the brains, or other deep tissue sites, can result in a 
severe illness leading to disability or death. Each year, an estimated 1.4 million cases of 
humans Salmonella infections occur in the United States causing 80,000-160,000 persons 
to seek medical attention, resulting in 16,000 hospitalization, and nearly 600 deaths(128). 
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Figure 1-1.  Proposed model of the AcrB–AcrA–TolC complex and the schematic 
mechanism of multidrug export mediated by AcrAB-TolC system. TolC structure15 is 
manually docked to AcrB. Dotted ovals indicate AcrA molecules. This figure was 
produced using Insight II/Discover (Biosym/MSI) (134).
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Antimicrobial agents are not essential for the treatment of most Salmonella
infections, but are commonly prescribed for person who seek medical attention (232). In 
surveys conducted by Centers for Disease Control (CDC) in 1990 (81) and 1995, 40% of 
persons with Salmonella infections who sought medical attention were treated with 
antimicrobial agents, suggesting that 32,000-64,000 persons with Salmonella infections 
are treated with antimicrobial agents. Ciprofloxacin was the most commonly prescribed 
antimicrobial agent for Salmonella infections. Ciprofloxacin,was used by approximately 
25% of those who received antimicrobial agents in the 1990 survey and 33% in 1995 
survey, suggesting >100,000 person with Salmonella infections have been treated with 
ciprofloxacin in the past 10 years in the United States (31).
In contrast to patients with uncomplicated gastroenteritis, effective antimicrobial 
agents are essential for the treatment of patients with bacteremia, meningitis, or other 
extraintestinal Salmonella infections (232). In approximately 6% of the confirmed cases 
reported to CDC, Salmonellae are isolated from specimens collected from extraintestinal 
sites, usually from blood (81, 163). Since approximately 40,000 culture-confirmed cases 
are reported to CDC each year, effective antimicrobial agents are critical and may be life 
saving for at least 2400 persons a year. The selection of antimicrobial agents for the 
treatment of invasive infections has become increasly restricted due to increasing 
antimicrobial resistance in Salmonella isolates. In the past, ampicillin, chloramphenicol, 
and trimethoprim-sulfamethoxazole were the “treatment of choice” for Salmonella
infections (36, 104, 209). Among randomly tested Salmonella isolates from humans 
tested at CDC in the National Antimicrobial Resistance Monitoring System in 2001, 17% 
isolates were resistant to ampicillin, 18% were resistant to trimethoprim-sulfmethoxazole, 
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and 12% resistant chloramphenicol (165). In contract, only 1% of Salmonella isolates are 
resistant to ceftriaxone or ciprofloxacin. For this reason, and because of clinical response 
and favorable pharmacodynamic properties, fluoroquinolone and third generation 
cephalosporin are the current drugs-of –choice for the treatment of invasive Salmonella
infections in adults and children respectively. Should Salmonella develop antimicrobial 
resistance to these two antimicrobial agents, suitable alternative antimicrobial agents are 
not currently available and serious adverse human health consequences are expected.
Brief overview of this dissertation
The work that will be described in this dissertation focuses on characterization of 
antimicrobial resistance in Salmonella and E. coli isolated from food and animals and the 
molecular mechanisms of antimicrobial resistance, particular the molecular mechanisms 
of fluoroquinolone resistance. Chapter 1 is an  “overview of antimicrobial resistance, 
mechanisms of antimicrobial resistance, and the public health concern about the 
antimicrobial resistance in foodborne pathogens”. In Chapter 2 “Characterization of 
multiple-antimicrobial-resistant Escherichia coli isolated from diseased chickens and 
swine in China”, E. coli isolates recovered from diseased piglets and chickens in China 
were characterized as to their O-serogroups, antimicrobial susceptibility phenotypes, 
presence of virulence genes and class 1 integrons.  Additionally, due to the high 
prevalence of fluoroquinolone resistance, the gyrA, gyrB, parC and parE genes from 40 
isolates were analyzed for the presence of mutations. The work described in Chapter 2 
was submitted to Journal of Clinical Microbiology. In the work described in Chapter 3 
“Characterization of Multiple-Antimicrobial-Resistant Salmonella isolated from meat 
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products in the United States and China” identified the phenotypes and genotypes, the 
presence of class I integrons, and the transfer of the antimicrobial resistance determinants 
via conjugative plasmid in antimicrobial-resistant in Salmonella from the United States 
and China. The work presented in Chapter 3 was published in the Applied Environmental 
Microbiology (33). Although genotype characterization can provide useful information 
about the potential virulence of bacteria, it is time consuming and expensive when using 
the PCR. Microarray is a powerful tool to analyze hundreds and thousands genes at one 
time. A DNA-based microarray method is described in Chapter 4 “Identification of 
Antimicrobial-Resistant and Virulence Genes in Salmonella and E. coli Using Microarray 
Analysis”. In this work, a microarray was constructed by printing 23 antimicrobial-
resistant genes and 22 virulent genes from E. coli and Salmonella onto microchips. The 
probes were prepared by random amplifying and DIG labeling of genomic and plasmid 
DNA. Twenty multiple-antimicrobial-resistant bacterial strains including 12 Salmonella
and eight E. coli were assayed for the presence of antimicrobial resistance and virulence 
genes using this microarray. Resistance to fluoroquinolone becomes a severe impact on 
human health. However, the mechanisms of fluroquinolone resistance in bacteria are not 
clearly understood. Therefore, in the work described in Chapter 5 “The Role of Target 
Mutation and Efflux in Fluoroquinolone-Resistant Salmonella” we studied the molecular 
mechanisms of fluoruoquinolone resistance including target gene mutation and efflux 
pumps using gene knockout chromosomal gene replacement techniques. 
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Chapter 2 Characterization of Multiple-Antimicrobial-Resistant 
Escherichia coli Isolated from Diseased Chickens and Swine in China
Abstract
Escherichia coli isolates from diseased piglets (n=89) and chickens (n=71) in 
China were characterized for O-serogroups, virulence genes, antimicrobial susceptibility, 
class 1 integrons, and mechanisms of fluoroquinolone resistance. O78 was the most 
common serogroup identified (63%) among the chicken E. coli isolates.  Most isolates 
were PCR positive for the increased serum survival gene (ISS) (97%) and the 
temperature-sensitive hemagglutinin gene (TSH) (93%).  The O-serogroups of swine E. 
coli were not those typically associated with pathogenic strains, nor did they posses 
common characteristic virulence factors. Twenty-three serogroups were identified among 
the swine isolates, however, 38 % were O non-typeable.  Overall, isolates displayed 
resistance to nalidixic acid (100%), tetracycline (98%), sulfamethoxazole (84%), 
ampicillin (79%), streptomycin (77%), and trimethoprim-sulfamethoxazole (76%).  
Among the fluoroquinolones, resistance ranged from 64% to levofloxacin, 79% to 
ciprofloxacin, and 95% to difloxacin.  DNA sequencing of gyrA, gyrB, parC, and parE
quinolone-resistance determining regions of 39 nalidixic acid-resistant E. coli revealed 
that a single gyrA mutation was found in all of the isolates;  mutations in parC together 
with double gyrA mutations conferred high-level  resistance (ciprofloxacin MIC ≥4 
µg/ml) to fluoroquinolones.  Class 1 integrons were identified in 17 (19%) of isolates 
from swine and 42 (47%) from chickens. The majority of integrons possessed genes 
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conferring resistance to streptomycin and trimethoprim.  These findings suggest that 
multiple-antimicrobial-resistant E. coli, including fluoroquinolone-resistant variants, are 
commonly present among diseased swine and chickens in China and the need for the 
introduction of surveillance programs in China to monitor antimicrobial resistance in 
pathogenic bacteria that can be potentially transmitted to humans from food animals.
Introduction
Although normally commensal in nature, certain strains of Escherichia coli are 
associated with a variety of infections in humans and animals.  In swine, pathogenic E. 
coli may cause neonatal and postweaning diarrhea and edema (18, 93).  In chickens they 
may cause infections of the respiratory tract and soft tissues resulting in colibacillosis, air 
saucculitis, and cellulitis (71). Virulence factors of swine E. coli include adhesins and 
several exotoxins (18, 62, 93).  For example, fimbrial types F4 (K88), F5 (K99), F6 
(987P), F107, and intimin, an outer membrane protein encoded by eae gene, play a role 
in adhesion to mucosal surfaces. Exotoxins produced by E. coli include heat-stable (STa 
and STb) and heat-labile (LT) enterotoxins, Shiga toxins (Stx1 and Stx2), and cytotoxic 
necrotizing factors (CNF1 and CNF2).  In swine, the most commonly reported E. coli 
serogroups associated with neonatal and postweaning diarrhea and edema belong to a 
limited number of serogroups including O8, O138, O139, O141, O147, and O157 (62, 63, 
93, 135).  Avian pathogenic E. coli most commonly belong to O1, O2, O78, and typically 
possess virulence factors such as lipopolysaccharide (LPS), temperature sensitive 
hemagglutination (TSH), and increased serum survival factor (ISS) (106, 129, 168, 215).  
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However, the distribution and frequencies of the most prevalent serogroups can vary 
considerably, both geographically and temporally.  
Antimicrobials are valuable tools to treat clinical disease and to maintain healthy
and productive animals. However, the treatment of whole herds and flocks with 
antimicrobials for disease prevention and growth promotion has become a controversial 
practice (211, 236). When antimicrobial agents are used indiscriminately in animals they 
may select for resistant bacteria that can eventually contaminate the human food supply.  
Of particular concern is the emergence of resistance to frontline antimicrobials such as 
the fluoroquinolones, which because of their low toxicity and relatively broad spectrum 
coverage, are extremely valuable for treating humans infections.  In addition to the 
human health concerns, antimicrobial-resistant pathogens also pose a severe and costly 
animal health problem, in that they may prolong illness and decrease productivity through 
higher morbidity and mortality. 
 Unfortunately, data on the prevalence of antimicrobial resistant veterinary 
pathogens are sparse, particularly in developing countries such as China.  Such data are 
urgently needed for science-based risk assessments focusing on the relative risks 
concerning use of antimicrobials in animal husbandry.  The study presented here was 
undertaken to determine the serogroups, virulence factors, antimicrobial susceptibility 
profiles, presence of class 1 integrons, and molecular mechanisms of fluoroquinolone 
resistance in E. coli isolated from diseased swine and chickens from farms in China.  The 
overall goal was to further our understanding of both pathogenic and antimicrobial-
resistance mechanisms present among  E. coli in food-producing animals from an area 
which has not instituted or benefited yet from a national surveillance system. 
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Materials and Methods
Bacterial isolates. A total of 160 E. coli isolates were analyzed in the study. These 
included 89 isolates recovered from fecal samples of 2 to 10 day-old piglets. The samples 
were recovered from animals experiencing diarrhea, located on three pig farms in 
Beijing, China during August 2000.  Seventy-one E. coli isolates were recovered from the 
livers of dead chickens from 10 poultry farms in Beijing and Heibei Province from 
January to October 2000.  All E. coli were isolated and purified on MacConkey agar 
(Difco Lab, Detroit, MI), and confirmed as E. coli with the API20E bacterial 
identification system (BioMerieux, Inc., Hazelwood, MO). 
Serogroup determination and identification of virulence genes.   Serogroups and 
virulence genes were determined at the Gastroenteric Disease Center of The Pennsylvania 
State University, State College, PA.  PCR was used to detect virulence genes, including 
LT, STa, STb, Stx1, Stx2, CNF1, CNF2, F4 (K88), F5 (K99), F6(987P), F18(F107), and 
intimin for swine E. coli, and K1, ISS, Tsh, and HlyE for avian E. coli using previously 
published primers and protocols (62, 129). 
Antimicrobial susceptibility testing. Antimicrobial susceptibility testing was 
performed according to the National Committee for Clinical Laboratory Standards 
(NCCLS) (139, 141).  Antimicrobial minimum inhibitory concentrations (MICs) of the E. 
coli isolates were determined via broth micro-dilution using the PASCO MIC/ID system 
(Becton Dickinson, MD) according to manufacturer’s instructions.  Antimicrobials 
included in the panels are listed in Table 2-1. In addition, MICs to nine quinolone 
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Table 2-1. Antimicrobial resistance phenotypes of E. coli isolates from diseased chickens and piglets










      Ceftiofur 8 ≤0.5 1 0 ≤0.5 ≤0.5 0 0
      Ceftriaxone 64 ≤0.025 ≤0.025 0 ≤0.025 ≤0.025 0 0
      Cephalothin 32 8 >32 27 16 32 20 23
Penicillins
      Amoxicillin/clavulanic acid 32/16 8/4 8/4 0 8/4 16/8 0 0
      Ampicillin 32 >32 >32 77 >32 >32 80 79
Sulfonamides & potentiated sulfonamides
      Sulfamethoxazole 512 >512 >512 79 >512 >512 89 84
       Trimethoprim/sulfamethoxazole 4-76 >4/76 >4/76 63 >4/76 >4/76 87 76
Quinolones and fluoroquinolones
      Ciprofloxacin 4 >16 >16 73 16 >16 84 79
      Difloxacin 4 >16 >16 91 >16 >16 98 95
      Enrofloxacin 2 >16 >16 90 >16 >16 76 83
      Gatifloxacin 8 16 >16 67 8 >16 75 72
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      Levofloxacin 8 16 >16 63 8 >16 65 64
      Nalidixic acid 32 >256 >256 99 >256 >256 100 99
      Orbifloxacin 8 >16 >16 76 >16 >16 96 87
      Sarafloxacin 0.25 >16 >16 100 16 >16 100 100
Phenicols
      Chloramphenicol 32 >32 >32 24 4 >32 63 46
Aminoglycosides
      Gentamicin 16 0.5 >16 30 2 >16 29 29
      Streptomycin 64 >256 >256 80 >256 >256 74 77
Tetracycline 16 >32 >32 100 >32 >32 96 98
abased on NCCLS standards, with the exception of streptomycin (139, 141).
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antimicrobials (Table 2-1) were determined using the Sensititre automated antimicrobial 
susceptibility system (Trek Diagnostic Systems, Westlake, OH).  E. coli ATCC 25922 and 
35218, Enterococcus faecalis ATCC 51299, and Pseudomonas aeuriginosa ATCC 27853 
were used as quality control organisms in all antimicrobial susceptibility tests.
Detection and sequence analysis of the quinolone resistance-determining regions 
(QRDR) in gyrA, gyrB, parC and parE.  Chromosomal DNA was prepared using a 
Wizard Genomic DNA Purification kit (Promega, Madison WI). The QRDR of gyrA, 
gyrB, parC, and parE were amplified by PCR using previously published primers (Table 
2) and protocols (56). The PCR was performed in a 50 µl volume consisting of 0.25mM 
of each deoxyribonucleotide, 1.5mM MgCl2, 1 U Gold Taq DNA polymerase, and 50 
pmol each primer. The temperature profile was: 95ºC for 10 min; 30 cycles of 95ºC for 
30 s, 55ºC for 45 s, and 72ºC for 45 s; and a final cycle of 72ºC for 7 min.
Predicted polypeptide products were analyzed for amino acid changes by 
comparison with wild type E. coli gyrA (accession number AE000312), gyrB 
(AE000447), parC (AE000384), and parE (AE000385). 
Detection and sequence analysis of class 1 integrons.  A PCR assay using 5’CS and 
3’CS primers (Table 1) was used to identify class 1 integrons in the E. coli isolates, 
according to the method of Zhao et al (244). Each of the amplified products was purified 
with a High PCR Purification kit (Roche, Indianapolis, MN) and sequenced at the Center 
for Agriculture Biotechnology, University of Maryland, College Park, MD.  Resultant 




Serogrouping and virulence genes. Six serogroups consisting of O1, O25, O78, O84, 
O88, and O160, were identified among the 71 E. coli isolates from diseased chickens 
(Table 2-2). The majority of the chicken isolates (63%) were identified as serogroup O78.  
Seven isolates were non-typeable.  E. coli isolates from chickens possessed multiple 
virulence factors (Table 2-2).  Ninety-seven percent of isolates were PCR positive for the 
increased serum survivial (iss) gene and 93% positive for the temperature-sensitive 
hemagglutinin (tsh) gene.  None of the isolates contained the hlyE gene.  Nine isolates 
carried all three virulence factors K1, ISS, and TSH, including four O25, two O78, two 
O88, and one non-typeable strain. Two isolates did not have any of the virulence factors 
examined. 
In contrast to the avian E. coli, the O-serogroups identified in swine E. coli were 
not those typically associated with pathogenic strains in the U.S.  Additionally, the swine 
isolates did not posses the characteristic toxin and fimbrial virulence factors associated 
with swine diarrhea (Table 2-3).  Twenty-three serogroups were identified among the 89 
E. coli isolates from swine, however, 38 % were non-typeable.  Among the 89 swine 
isolates, 10% contained Stx1, 7% contained CNF2, and 4 contained either STa, CNF2, 
K99, or F107.  Two E. coli isolates possessed two virulence factors: O153 (CNF2, K99) 
and O171 (Stx1, CNF2).  However, most (81%) isolates did not contain any of the 
virulence factors screened for in this study. 
Antimicrobial resistance. Most E. coli isolates recovered from diseased chickens and 
swine were resistant to multiple classes of antimicrobials (Table 2-1).  The
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Table 2-2. Primer sequences used to amplify class 1 integrons and the quinolone 
resistance-determining regions (QRDR) of gyrA, gyrB, parC and parE
PCR target Primers Primer sequence (5’ –  3’) Reference
Class I integron 5’CS GGCATCAAGCACAAGC (244)
3’CS AAGCAGACTTHACTGAT
QRDR of gyrA gyrA-1 ACGTACTAGGCAATGACTGG (56)
gyrA-2 AGAAGTCGCCGTCGATAGAA
QRDR of gyrB gyrB-1 TGTATGCGATGTCTGAACTG (56)
gyrB-2 CTCAATAGCAGCTCGGAATA
QRDR of parC parC-1 CAGACTGCCAGGAACGCGAT (56)
parC-2 AGCCAAGCGCGGTGATAAGC
QRDR of parE parE-1 TACCGAGCTGTTCCTTGTGG (56)
parE-2 GGCAATGTGCAGACCATCAG
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Table 2- 3. Serogroups and virulence genes of E. coli isolates from diseased chicken and swine




K1 ISS Tsh HlyE O-group
No. of 
isolates
STa Stx1 CNF1 CNF2 K99 F107
O1 2 0 1 1 0 O1 5 0 1 0 0 0 0
O25 4 4 4 4 0 O21 7 0 0 1 0 0 0
O78 45 2 45 45 0 O101 8 0 1 0 1 1 (O153) 0
O84 6 0 6 6 0
O9, O88, O153, 
O171




O88 6 2 6 3 0
O19, O25, O91, 
O142,O149, 
O157, O159
14 (2 each) 0 2 (O91) 0 1 (O159) 0 1 (O149)
O160 1 0 0 0 0
O33, O35, O54, 
O79,O114, 
O160, X3, X13, 
X28
9 (1 each) 1 (O114) 1 (X13) 0 0 0 0
NT 7 1 7 7 0 NT 34 0 3 0 2 0 0
Total 71 9 69 66 0 Total 89 1 9 1 6 1 1
K1: capsule antigen K1;  ISS: increased serum survival factor; Tsh: temperature sensitive hemagglutination; HlyE: hemolysin E; STa: 
heat-stable enterotoxins; Stx1: Shiga toxin 1; CNF1 and CNF2: cytotoxic necrotizing factors 1 and 2; K99: fimbrial type 5; F107: 
fimbrial type 107; X: experimental O group; NT: nontypeable.
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majority of isolates were resistant to tetracycline (98%), sulfamethoxazole (84%), 
ampicillin (79%), streptomycin (77%), and trimethoprim/sulfamethoxazole (76%).  
Resistance to chloramphenicol among the swine isolates (63%) was significantly higher 
(p < 0.05) than resistance among chicken isolates (24%).  Surprisingly, all E. coli isolates, 
regardless of their animal origin, were resistant to the quinolone antimicrobial, nalidixic 
acid.   Due to the high incidence of quinolone resistance, all isolates were also tested 
against a panel of veterinary and human use fluoroquinolones. Among these isolates, 
fluoroquinolone resistance ranged from 64% to levofloxacin, 79% to ciprofloxacin, and 
95% to difloxacin.  E. coli isolates of both avian and swine origin displayed elevated 
levels of resistance to all fluoroquinolones tested (Table 2-3).  
With regards to multi-drug resistance profiles, all isolates from swine were 
resistant to more than 8 of the 19 antimicrobials tested, 86% were resistant to more than 
11 antimicrobials, and 2% were resistant to 16 antimicrobials. All isolates recovered from 
diseased chicken were resistant to at least 3 of the 19 antimicrobial tested.  Fifty-six 
(79%) avian E. coli isolates were resistant to more than eight antimicrobials, and two 
(3%) were resistant to 16 antimicrobials.  All E. coli isolates from this study were 
susceptible to ceftiofur, ceftriaxone and, amoxicillin-clavulanic acid.
Topoisomerase point mutations in fluoroquinolone-resistant E. coli. All quinolone-
resistant E. coli isolates were tested for amino acid substitutions in GyrA and 39 
representative isolates (20 from swine and 19 from chickens) were also tested for amino 
acid mutations in GyrB, ParC, and ParE (Table 2-4).  All nalidixic acid resistant E. coli
possessed a mutation at position 83 in GyrA (S83L).  Single mutations (S83L) and double 
mutations (S83L and D87A, D87N, D87G or D87Y) were found in GyrA, whereas no 
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Table 2-4. Amino acid substitutions in DNA gyrase and topoisomerase IV and corresponding fluoroquinolone resistance profiles 
among E. coli isolated from diseased chickens and swine (n=39).
Amino Acid Substitutiona MIC range (µg/ml)
# of isolates
GyrA ParC ParE Nalidixic acid Enrofloxacin Ciprofloxacin Gatifloxacin
1 S83L 256 0.5 0.25 0.25
3 S83L S80R >256 2-8 1-4 1-4
4 S83L S80I >256 1-4 0.5-4 0.5-2
1 S83L D87N S80I >256 16 8 4
1 S83L D87G S80I >256 16 16 8
1 S83L D87N E84K >256 >16 16 8
23 S83L D87N S80I >256 16->16 8->16 4->16
2 S83L D87N S80I S459A >256 16->16 8->16 8->16
1 S83L D87Y S80I >256 16->16 8->16 8->16
1 S83L D87Y S80I S459A >256 16->16 8->16 8->16
1 S83L D87Y S80I N463D >256 16->16 8->16 8->16
aSubstituted amino acids, and the position number; e.g. S83L indicates substitution of  a leucine for a serine at position 83. 
Aminoacids: S, serine; L, leucine; D, aspartic acid; N, asparagine ; Y, tyrosine;  I, isoleucine; R, arginine; G, glycine; alanine. 
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mutations in GyrB and only single mutations, S80I, S80R or E84K in ParC, and S459A 
or N463D in ParE were identified.  Among the 38 isolates that possessed mutations in 
ParC, the most common was S80I (90%), followed by S80R (8%).  The most frequent 
pattern of mutations (n=18) included a double mutation in GryA (S83L, D87N) and a 
single mutation in ParC (S80I).  All 18 isolates exhibited resistance to both enrofloxacin 
and ciprofloxacin and 94% were resistant to gatifloxacin.  Less common mutations 
included 4 isolates with a mutation in GryA (S83L) and in ParC (S80I) and 4 isolates 
with a double mutation in GyrA (S83L, D87N), and single mutation in ParC (S80I) 
(Table 2-4).  One isolate possessed only a S83L substitution in GyrA and was nalidixic 
acid resistant, but susceptible to fluoroquinolones tested with the exception of 
sarafloxacin (MIC 0.5 µg/ml).  
Presence of Class 1 integrons.  All veterinary E. coli isolates were characterized for the 
presence of class 1 integrons since a recent study documented plasmid-mediated 
quinolone resistance in clinical E. coli isolates from Shanghai, China, and suggested the 
possibility that the gene, qnr, is possibly located in a class 1 integron (15, 19, 178, 185, 
229).  Nineteen percent of E. coli isolates recovered from swine possessed class 1 
integrons, with sizes ranging from ca. 0.7 to 2.0 Kb. Nine different serotypes of swine E. 
coli isolates harbored integrons, however, the majority of serotypes harboring these 
integrons were non-typeable.  Ten isolates carried a 1.5-kb integron containing the dhfr1 
and aadA1 genes (Table 2-5), which confer resistance to trimethoprim and streptomycin, 
respectively.  Three isolates carried a 2.0-kb integron.  In two isolates, the 2.0-kb integron 
contained dhfr12 and aadA2, and in one strain it contained dhfr17 and aadA2. Two 
isolates contained a 1.0-kb integron (aadA1), with one strain containing an additional
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Table 2-5. Integrons and their gene cassettes in swine and avian E. coli
No. of StrainsSize of Integron 
(Kb) Swine (n=89) Avian (n=71)
Gene Cassettea
2.0 2 0 dhfr 12, aadA2
2.0 1 0 dhfr17, aadA2
1.5 10 33 dhfr 1, aadA1
1.5 0 1 dhfr 17, aadA2
1.0 3 3 aadA1
0.7 0 1 dhfr13
1.5, 1.0 1 0 dhfr17, aadA2; aadA1
1.5, 0.7 0 4 dhfr17, aadA2; dhfr13
aaad, aminoglycoside adenyltransferase; dhfr, dihydrofolate reductase.
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1.5-kb integron (dhfr1and aadA1). The majority (59%) of avian E. coli contained class 1
integrons ranging in size from 0.7 kb to 1.5 kb (Table 5).  Integrons were found in avian 
isolates from 4 of the 6 serogroups identified, however, the majority were found within 
isolates possessing serogroup O78 (35/45).  Thirty-four of these isolates contained a 1.5-
kb integron with dhfr1 and aadA1 and one isolate contained a 1.5-kb integron with 
dhfr17and  aadA2.  Six isolates contained both of 1.5kb integron (dhfr1 and aadA1) and 
0.7kb integron (dhfr13).  Two isolates contained 1.0kb integron with aadA1 gene.  No 
class 1 integrons were found that possessed the plasmid mediated quinolone-resistance 
gene, qnr.
Discussion
More than 160 O-serogroups have been identified in E. coli.  However, disease-
causing E. coli typically consists of a relatively few serogroups.  In this study, 66% of the 
E. coli isolates from chickens belonged to serogroups (O1 and O78) typically associated 
with colibacillosis.  The ability of these isolates to cause disease in the birds may have 
been attributable, in part, to the fact that they possessed ISS and TSH - virulence factors 
known to increase bacterial resistance to serum and colonization of internal organs of 
infected chickens (106, 129).  The finding that most isolates are O78 might prove useful 
to poultry farms in combating infection and offer an alternative to antibiotics in the form 
of bacterin vaccines.  In contrast to those from chickens, E. coli from diseased piglets 
were found to have O-serogroups different from their counterparts in other regions of the 
world.  These isolates did not possess the virulence factors seen in the serogroups such as 
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O8, O147, O149, and O157 that are often associated with diarrhea in piglets (181). Thus, 
while it is possible that other colonization factors or enterotoxins may have contributed to 
the pathogenicity of these E. coli, further study is clearly needed to determine the 
underlying pathogenicity mechanisms.
Similar to the findings of previous studies (15, 19, 178, 185, 229), most E. coli
isolates of avian and swine origin described here were resistant to tetracyclines, 
aminoglycosides, and sulfonamides. A significantly higher number of the swine E. coli
isolates were resistant to chloramphenicol compared to the chicken isolates.  This may be 
related to the broad use of florfenicol to treat swine diseases in China as compared to its 
limited use in avian husbandry.  Perhaps the most striking finding from this study was the 
widespread resistance to quinolones and fluoroquinolones.  All E. coli isolates were 
resistant to nalidixic acid and sarafloxacin.  More than 70% were resistant to 
ciprofloxacin, and more than 60% were resistant to the newer human fluoroquinolones, 
gatifloxacin and levofloxacin.  Somewhat similar findings have been reported in a recent 
study of clinical E. coli isolates from China, wherein greater than 50% of all isolates were 
resistant to ciprofloxacin (221).  Similar findings were also reported for E. coli isolates 
recovered from chickens and swine in Spain where 90% of chicken isolates and 50% of 
swine isolates were resistant to ciprofloxacin (178, 222).  Fluoroquinolone resistance in 
these isolates, coupled with the observation of widespread multiple antimicrobial 
resistance (e.g., 80% of the isolates from this study were resistant to eight or more 
antibiotics) likely portends further complications in treatment of E. coli infections in 
humans and animals from this region.  
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The molecular investigations into the underlying quinolone resistance mechanisms 
revealed that all quinolone resistant isolates possessed the typical mutations in the 
topoisomerase genes, gyrA and parC, as reported by other studies (12, 84, 105).  
Resistance to fluoroquinolones has most frequently been associated with alterations at 
S83L and D87G in the quinolone resistance-determining region (QRDR) of the DNA 
gyrase gene gyrA (12, 98).  Our results are in agreement with previous reports as all 
quinolone resistant E. coli isolates, regardless of swine or avian origin, possessed a point 
mutation in GyrA of S83L or a double mutation of S83L and either D87A (n=1), D87G 
(n=1), D87Y (n=3), or D87N (n=26).  Our finding that the most common mutation at 
codon 87 in GyrA resulted in substitution of asparagine for aspartic acid is consistent 
with other studies (12, 84, 103, 105).  With regards to correlation of mutations with 
decreased susceptibilities to tested fluoroquinolone agents, isolates with single mutations 
in GyrA had relatively low (≤4 µg/ml) MICs to enrofloxacin and ciprofloxacin (Table 4), 
whereas many E. coli isolates with double GyrA and single ParC mutations had 
correspondingly high MICs (≥8 µg/mL) to these drugs.  
Among the 38 isolates that possessed ParC mutations, almost all possessed a 
mutation at position 80 resulting in an amino acid substitution of either arginine (S80R, 
n=3) or isoleucine (S80I, n=34), with the exception of one swine isolate which carried the 
E84K mutation in ParC.  Mutations in parC at S80I or E84K have been associated with 
high-level resistance to fluoroquinolones, and have been detected in clinical strains 
carrying a gyrA mutation (12, 84, 105).  As expected, single mutations observed in ParC
always coincided with mutations in GyrA among the veterinary E. coli isolates in this 
study.  Mutations in gyrB and parE have been associated with quinolone resistance (83), 
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however, the mutation frequency is much lower compared to gryA and parC.  
Additionally, the ParE mutations reported here have to the best of our knowledge not 
been reported previously (23, 103).  However, it is difficult to determine how much these 
mutations contribute to decreased fluoroquinolone susceptibility as all isolates that 
possessed ParE mutations also carried mutations in GyrA and ParC.  Other mechanisms 
of fluoroquinolone resistance exist besides mutations in the genes encoding DNA gyrase 
and topoisomerase IV.  These include decreased production of porin proteins and up-
regulation of multidrug resistance efflux pumps (68).  Though we did not explore the 
contribution of these other mechanisms to the fluoroquinolone resistant phenotypes 
observed in this study, it is more than likely that they play a role in the evolution of 
fluoroquinolone resistance.  The isolates in this study are the subject of future research to 
determine if efflux mechanisms are also involved in the quinolone resistant phenotypes.
Regarding the genetics of resistance to other antimicrobials in the E. coli isolates 
from this study, integrons were likely important, both in terms of the mechanisms of 
resistance and in the dissemination of resistance genes (24, 206).  Integrons are known to 
be associated with multiple-drug resistance in enteric organisms, and class 1 integrons 
specifically, have been shown important in the dissemination of intI, sulI, and one or 
more antimicrobial resistance gene cassettes among Gram-negative bacteria (122, 244).  
The findings from this study are consistent with most previous data in that varying sizes 
of integrons were found in the E. coli isolates, and they contained genes for resistance to 
aminoglycosides, trimethoprim, and β-lactams (12, 98).  More recently, Wang et al. (222)
reported the occurrence of a gene in a class I integron, termed qnr, which provides low 
level quinolone resistance.  They found qnr in fluoroquinolone resistant humans clinical 
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E. coli isolates from Shanghai, China, suggesting the possibility that qnr was also present 
in some of our avian and swine strains.  None of the integron-positive avian or swine E. 
coli isolates yielded qnr (data not shown) or a qnr like gene upon DNA sequencing, 
however, further studies are ongoing on these isolates to determine if qnr is indeed 
present, but not in the class 1 integrons previously identified.
In summary, because trained practitioners are unavailable in many regions of 
developing countries, regulations on the veterinary use of antibiotics are poorly enforced 
or absent in many developing countries.  Consequently, there is opportunity for the 
inappropriate use of antibiotics in both humans and veterinary medicine.  With 
concentrated livestock production increasing in developing countries, reliance on 
antimicrobials will likewise expand.  Our data suggest that a lack of restrictions on 
antimicrobial use in food animals in China has resulted in the dissemination of multiple 
drug resistant pathogenic E. coli isolates, including fluoroquinolone resistant variants.  
Research is needed to determine the role of antimicrobial use in animal production 
environments on emergence and spread of resistance in both veterinary and humans
medicine worldwide, especially in developing countries.  It is also important that 
antimicrobial prudent use guidelines be developed in conjunction with the establishment 
of surveillance programs for monitoring antimicrobial resistance in pathogenic bacteria 
that can be transmitted to humans from food animals.  This information should ultimately 
provide important information for the development of public health policy for use of 
antimicrobials in food animal production in developing countries.
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Chapter 3 Characterization of Multiple-Antimicrobial-Resistant Salmonella
Serovars Isolated from Retail Meats 
Abstract
One hundred thirty-three Salmonella isolates recovered from retail meats purchased 
in the United States and the People’s Republic of China were assayed for antimicrobial 
susceptibility, the presence of integrons and antimicrobial resistance genes, and 
horizontal transfer of characterized antimicrobial resistance determinants via conjugation.  
Seventy three (82%) Salmonella isolates were resistant to at least one antimicrobial. 
Resistance to following antibiotics was common among the U.S. isolates was resistance 
to tetracycline (68%), streptomycin (61%), sulfamethoxazole (42%), and ampicillin 
(29%). Eight Salmonella isolates (6%) were resistant to ceftriaxone. Fourteen isolates 
(11%) from China were resistant to nalidixic acid and displayed decreased susceptibility 
to ciprofloxacin. A total of 19 different antimicrobial resistance genes were identified in 
30 multidrug-resistant Salmonella isolates. The blaCMY-2 gene, encoding a class A AmpC 
β-lactamase, was detected in all 10 Salmonella isolates resistant to extended spectrum β-
lactams.  Resistance to ampicillin was most often associated with a TEM-1 family β-
lactamase gene. Six aminoglycoside resistance genes aadA1, aadA2, aacC2, Kn, aph(3)-
IIa, aac(3)-IVa, were commonly present in the Salmonella isolates.  Sixteen (54%) of 30 
Salmonella isolates tested had integrons ranging in size from 0.75 to 2.7kb. Conjugation 
studies demonstrated plasmid-mediated transfer of genes encoding CMY-2 and TEM1-
like β-lactamases. These data indicate that Salmonella recovered from retail raw meats 
are commonly resistant to multiple antimicrobials, including those such as ceftriaxone 
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used for treating salmonellosis. Genes conferring antimicrobial resistance in Salmonella
are often carried on integrons and plasmids, and could be transmitted through 
conjugation.  These mobile DNA elements have likely played an important role in 
transmission and dissemination of antimicrobial resistance determinants among 
Salmonella. 
Introduction
The emergence of antimicrobial-resistant bacterial pathogens has become a major 
public health concern.  The use of antimicrobials in any venue, including for disease 
treatment and growth promotion in domestic livestock, can potentially lead to widespread 
dissemination of antimicrobial-resistant bacteria (70, 205, 236).  In recent years, testing 
of Salmonella isolates from the United States and other countries has shown that an 
increasing proportion are multidrug-resistant (34, 69, 74, 200). Of particular concern is 
the isolation of ceftriaxone- and ciprofloxacin-resistant Salmonella, because of the 
importance of these two agents in treating Salmonella infections in children and adults 
(34, 54, 231), respectively. 
Resistance to antimicrobial agents in bacteria is mediated by several mechanisms, 
including 1) changes of bacterial cell wall permeability, 2) energy-dependent removal of 
antimicrobials via membrane bound efflux pumps, 3) modification of the site of drug 
action, and 4) destruction or inactivation of antimicrobials (13, 186). Acquired 
antimicrobial resistance phenotypes most often develop via conjugative transfer of 
plasmids (59, 66, 73). Plasmids may  carry class I integrons, mobile DNA elements 
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important in the proliferation of bacterial multidrug resistance, especially among the 
Gram-negative enteric species (11, 50, 162, 214). Integrons primarily have been found 
located within transposons Tn402 and Tn21, which in turn reside on broad-host-range 
plasmids or the lncF plasmid (28, 217).  By incorporating into transposons and plasmids, 
integrons participate in the capture and dissemination of resistance genes among bacteria.
Molecular genetic techniques have been used to characterize antimicrobial-
resistant Salmonellae, especially S. Typhimurium DT104 (22, 24, 42, 144, 170). For 
instance, variant Salmonella genomic island 1 (SGI1) multidrug resistance (MDR) 
regions, consisting of integrons encoding different resistance genes, have been found 
located in the chromosomal DNA of S. Typhimurium DT104 and Agona (22). The 
formation of these multidrug resistance clusters is hypothesized to favor the expression of 
a large number of resistance genes and enhance their transfer to other bacteria. Also, 
because class I integrons have become integrated into the chromosome of S. 
Typhimurium DT104 and Agona, they are able to persist even in the absence of 
antimicrobial selection (22, 42)  with no apparent fitness cost to the cell.  This has lead, in 
the case of DT104, to a stable and widely disseminated clone of multidrug-resistant S. 
Typhimurium.
The objectives of this study were to determine the antimicrobial susceptibility 
phenotypes of Salmonella isolated from retail meats from the Washington D.C. area in 
the United States and from China, and to characterize the genetic mechanisms underlying 
antimicrobial-resistant phenotypes observed for the isolates. We also examined select 
isolates for the ability to donate resistance genes via conjugative transfer of plasmids to 
E. coli.  Our goal was to advance understanding of the molecular genetic mechanisms 
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involved in the emergence and dissemination of antimicrobial-resistant Salmonella.
Materials and Methods
Salmonella isolates.  A total of 133 Salmonella isolates were included in the study. 
Eighty-nine were recovered from retail ground meat samples of chicken, turkey, pork, 
and beef purchased in the Washington D.C. area, including 45 from samples purchased 
between June and September 1998, and 44 from samples purchased between August 1999 
to August 2000. The other 44 Salmonella isolates were isolated from samples of pork, 
beef, chicken, and mutton purchased in 10 provinces in China, from October 1999 to 
December 2000.
All Salmonella isolates were recovered from meats using methods described in 
the 8th edition of the U.S. Food and Drug Administration Bacteriological Analytical 
Manual (61).  The isolates were further identified with API identification kits 
(BioMerieux, Marcy, France) and serotyped with commercial antiserum (Difco, Detroit, 
MI) according to manufacturers’ instructions. 
Antimicrobial susceptibility testing. Antimicrobial minimum inhibitory 
concentrations (MICs) of the 133 Salmonella isolates were determined using the 
Sensititre automated antimicrobial susceptibility system (Trek Diagnostic Systems, 
Westlake, OH) and interpreted according to the National Committee for Clinical 
Laboratory Standards (NCCLS) for microdilution broth methods (138, 140). The 17
antimicrobials used and their recommended resistance breakpoints are presented in Table 
3-1. E.  coli ATCC 25922, 35218, Enterococcus faecalis ATCC 29212, Enterococcus 
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faecalis ATCC 29212, Staphylococcus aureus ATCC29213, and Pseudomonas 
aeruginosa ATCC 27853 were used as quality control organisms. 
DNA isolation, PCR, and gene sequence analysis. Based on serotypes and 
antimicrobial resistance profiles, 30 multidrug-resistant Salmonella isolates were selected 
for further characterization of antimicrobial resistance genes and class 1 integrons. 
Chromosomal and plasmid DNA of the bacterial isolates were isolated using the Wizard 
Genomic DNA Purification kit (Promega, Madison WI) and the High Plasmid 
Purification kit (Roche, Indianapolis IN), respectively. The quantity of the DNA was 
measured using a Smartspect 3000 spectrophotometer (BioRad, Hercules, CA). Sixty-one 
pairs of oligonucleotide primers (Table 3-2) were designed to target 61 antimicrobial 
resistance genes that confer resistance to 6 categories of antimicrobial agents, including 
β-lactams, aminoglycosides, phenicols, tetracycline, trimethoprim, and sulfonamides. All 
primers were designed to differentiate the specific gene sequence of interest, except for 
the blaTEM-1 primers that amplify the entire family of blaTEM genes. The primers were 
designed using the OLIGO 5.0 software program (National Biosciences, Inc., Plymouth, 
MN) and synthesized commercially (Invitrogen, Carlsbad, CA). PCR was performed in a 
total volume of 50 µl distilled H2O including 0.25mM of each deoxyribonucleotide, 
1.5mM MgCl2, 0.2 U Gold Taq DNA polymerase, and 50 pmol each primer. The 
temperature profile included an initial template denaturation step at 95ºC for 10 min, 
followed by 30 cycles of 95ºC for 30 s, 55ºC for 1 min, and 72ºC for 1 min, and a final 
step at 72ºC for 7 min (8). The presence of class I integrons among the 30 Salmonella
isolates was determined by PCR using primers 5’CS (5'-GGCATCCAAGCACAAGC-3')
69
Table 3-1. Antimicrobial resistance of Salmonella isolates from retail meats in the United States and China
Antimicrobials Breakpoint US isolates 1998-2000 (n=89) Chinese isolates 1999-2000 (n=44)








    Ampicillin 32 29 0 39 2
    Amoxicillin/clavulanate 32 21 9 0 2
    Cephalothin 32 24 4 2 0
    Ceftiofur 8 19 1 0 0
    Ceftriaxone 64 9 10 0 0
    Cefoxitin 32 18 0 0 0
Phenicols
    Chloramphenicol 32 11 0 20 2
Tetracycline 16 68 0 43 2
Aminoglycosides
    Amikacin 64 0 0 0 0
    Apramycin 32 0 0 0 0
    Gentamycin 16 2 0 2 0
    Kanamycin 64 6 0 11 0
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    Streptomycin 64 61 0 27 0
Sulfonamides
    Sulfamethoxazole 512 42 3 16 0
    Trimethoprim-sulfamethoxazole 4/76 9 0 9 0
Quinolones and fluoroquinolone
    Nalidixic acid 32 0 0 32 0
    Ciprofloxacin 4 0 0 0 0
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Tble3-2. Sequences of PCR oligonucleotide primers used for the identification of antimicrobial resistance genes in Salmonella isolates 
Sequence of olignucleotide primers
Antimicrobials Resistance 





blaCMY-2 TGG CCG TTG CCG TTA TCT AC      CCC GTT TTA TGC ACC CAT GA 870 X91840
blaCMY-9 TCA GCG AGC AGA CCC TGT TC    CTG GCC GGG ATG GGA TAG TT 874 AB049588
blaFOX-1 CAG CCG ATG CTC AAG GAG TA    CAA CCC AGC CCC TGA GTC AT 761 X77455
blaDHA-1 GCC GGT CAC TGA AAA TAC AC   TAC GGC TGA ACC TGG TTG TC 762 Y16410
blaMI1 AGC GTC GCC AGT TCT GCA TT      GAC CGG CCA GTT GAG CAT CT 858 M37839
blaSHV-1 GGC CGC GTA GGC ATG ATA GA     CCC GGC GAT TTG CTG ATT TC 714 F148850
blaTEM-1 CAG CGG TAA GAT CCT TGA GA    ACT CCC CGT CGT GTA GAT AA 643 AF309824
blaCTX-M1 AAC CGT CAC GCT GTT GTT AG     TTG AGG CTG GGT GAA GTA AG 766 X92506
blaCTX-M2 GGC GTT GCG CTG ATT AAC AC    TTG CCC TTA AGC CAC GTC AC 486 X92507
blaCTM-M14 GCC TGC CGA TCT GGT TAA CT     GCC GGT CGT ATT GCC TTT GA 358 AF252622
blaVEB-1 TAG CCG TTT TGT CTG AGA TA     TTA CCC CAA CAT CAT TAG TG 543 AF205943
blaOXA-1 AAT GGC ACC AGA TTC AAC TT    CTT GGC TTT TAT GCT TGA TG 595 J02976
blaOXA-2 CAA GCC AAA GGC ACG ATA GT    ACG ATT GCC TCC CTC TTG AA 644 X07260
blaOXA-7 GAA GCC GTC AAT GGT GTT TT     ATG CCC TCA CTT GCC ATG AT 686 X75562
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blaPSE-1 TGC TTC GCA ACT ATG ACT AC      AGC CTG TGT TTG AGC TAG AT 438 AF153200
blaIMP-1 TGA GGC TTA CCT AAT TGA CA      TCA GGC AAC CAA ACC ACT AC 324 S71932
Aminoglycoside
aac(3)-Ia TGA GGG CTG CTC TTG ATC TT        ATC TCG GCT TGA ACG AAT TG 436 X15852
aac(3)-IIa CGG CCT GCT GAA TCA GTT TC        AAA GCC CAC GAC ACC TTC TC 439 X13543
aacC2 GGCAATAACGGAGGCAATTCGA   CTCGATGGCGACCGAGCTTCA 450 X51534
aacC4 ACTGAGCATGACCTTGCGATGCTCTA  TACCTTGCCTCTCAAACCCCGCTT 436 AJ009820
aac(3)-IVa GAT GGG CCA CCT GGA CTG AT       GCG CTC ACA GCA GTG GTC AT 462 X01385
aac(6’) TTG GAC GCT GAG ATA TAT GA      GCT CCT TTT CCA GAA TAC TT 476 M18086, 
aph(2’’) GAC CGT GTT CTT GAA TTC TA        GCG GGA ATC TTT TAG CAT TA 464 M13771
ant(3’’)-Ia CGC CGA AGT ATC GAC TCA AC      GCG GGA CAA CGT AAG CAC TA 559 X02340
aadD F, ATATTGGATAAATATGGGGAT TCCACCTTCCACTCACCGGTT 161 AF051917
ant(6)-Ia GCC GGA GGA TAT GGA ATT AT      TCA GCG GCA TAT GTG CTA TC 666 AF299292
Kn ACTGGCTGCTATTGGGCGA        CGTCAAGAAGGCGATAGAAGG 515 U66885
aph(3’)-IIa TCC GGT GCC CTG AAT GAA CT        ACG GGT AGC CAA CGC TAT GT 519 V00618
aph(4)-Ia TCT CGG AGG GCG AAG AAT CT       TTG CCG TCA ACC AAG CTC TG 763 V01499
Tetracycline
tetA GCG CCT TTC CTT TGG GTT CT            CCA CCC GTT CCA CGT TGT TA 831 X00006
73
tetB CCC AGT GCT GTT GTT GTC AT        CCA CCA CCA GCC AAT AAA AT 723 V00611
tetC TTG CGG GAT ATC GTC CAT TC        CAT GCC AAC CCG TTC CAT GT 1019 Ab023657
tetD CTG GGC AGA TGG TCA GAT AA      TGA CCA GCA CAC CCT GTA GT 832 X65876
tetE CGT CGC CCT GTA TTG TTA CT        TGG TCA GCA CCC CTT GTA AT 814 l06940
tetG AGC AGG TCG CTG GAC ACT AT       CGC GGT GTT CCA CTG AAA AC 623 Af07155
Trimethoprim
dhfrI CGG TCG TAA CAC GTT CAA GT       CTG GGG ATT TCA GGA AAG TA 220 Af382145
dhfrII AGT TTG CGC TTC CCC TGA GT          CTT AGG CCA CAC GTT CAA GTG 194 Af083409
dhfrIII ACC TGC CGA TCT GCG TCA T           TCG CAG GCA TAG CTG TTC 387 J03306
dhfrV TTG GTT GCG GTC CAC ACA TA         CTC CTT CCG GCT CAA TAT C 330 X12868
dhfrVI GTT TCC GAG AAT GGA GTA AT      ACT AAA CGC AAC GCA TAG TA 508 Z86002
dhfrVII AGC AAA AGG TGA GCA GTT AC     GTG CTG GAA CGA CTT GTT AG 419 X58425
dhfrVIII  TTG GGA AGG ACA ACG CAC TT      ACC ATT TCG GCC AGA TCA AC 382 U10186
dhfrIX TCA GAT TCC GTG GCA TGA AC     AAT GGT CGG GAC CTC AGA T 400 X57730
dhfrX  ACC AGA GCA TTC GGT AAT CA      TTG GAT CAC CTA CCC ATA GA 445 l06418
dhfrXII  AAA TTC CGG GTG AGC AGA AG      CCC GTT GAC GGA ATG GTT AG 429 Z21672
dhfrXIII  GCA GTC GCC CTA AAA CAA AG     GAT ACG TGT GAC AGC GTT GA 294 Z50802
dhfrXV GCC GTG GGT CGA TGT TTG AT          TTC ACC ACC ACC AGA CAC A 395 Z83311
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dhfrXVI GCT CTC CCA AAT CGA AAG TA       ATT GCA GGC GCT TGT TAA CT 332 Af077008
Sulfornamide
sulI TCA CCG AGG ACT CCT TCT TC         CAG TCC GCC TCA GCA ATA TC 331 X15024
sulII CCT GTT TCG TCC GAC ACA GA       GAA GCG CAG CCG CAA TTC AT 435 M36657
Chloramphenicol
cat1 CTT GTC GCC TTG CGT ATA AT           ATC CCA ATG GCA TCG TAA AG 508 M64281
cat2 AAC GGC ATG ATG AAC CTG AA ATC CCA ATG GCA TCG TAA AG 547 Aj401047
cat3 ATC GGC ATC GTT TAC CAT GT           ATC CCC TTC TTG CTG ATA TT 531 Ay042185
cmlA CGC CAC GGT GTT GTT GTT AT          GCG ACC TGC GTA AAT GTC AC 394 Af078527
cmlB ACT CGG CAT GGA CAT GTA CT       ACG GAC TGC GGA ATC CAT AG 840 Af034958
flo CTG AGG GTG TCG TCA TCT AC          GCT CCG ACA ATG CTG ACT AT 673 Af252855.
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and 3’-CS (5'-AAGCAGACTTGACTGAT-3') as previously described (244).
All PCR products were purified with High PCR Purification kits (Roche,
Indianapolis, MN) and sequenced at the University of Maryland Center of Agriculture 
Biotechnology, College Park, MD.  Resultant DNA sequence data were compared to data 
in the GenBank database using the BLAST algorithm (7) available at the National Center 
of Biotechnology Information’s web site (www.ncbi.nlm.nih.gov). 
Conjugation experiments  Multidrug-resistant Salmonella isolates recovered from 
retail meats (10 from the Washington DC area and 4 from China) were used as donor 
strains in conjugation experiments to study antimicrobial resistance gene transfer.  Two 
nalidixic acid-resistant E. coli strains (1003 and 1016) were used as recipient strains. 
Conjugation was performed using the filter mating method as described previously (40). 
Briefly, donor and recipient cells (1:10) were mixed in Luria-Bertani broth (Difco). The 
mixture was then collected on a 0.45 µm pore-size filter and incubated on blood agar 
plates (BAP) at 37°C overnight. The mating mixture was washed from the filter and 
spread onto BAP containing a combination of nalidixic acid (60µg/ml) and streptomycin 
(50µg/ml), or nalidixic acid (100µg/ml) and kanamycin (50µg/ml). Bacterial colonies on 
BAP containing appropriate antibiotics were transferred onto MacConkey agar (Difco) 
plates and incubated overnight at 37oC.  Presumptive E. coli transconjugants  were 
confirmed as E. coli via the API test, and assayed for susceptibility to 17 antimicrobial 
agents.  Transfer of antimicrobial resistance genes was confirmed by PCR using primers 
shown in Table 2. 
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Results
Antimicrobial resistance of Salmonella isolates.  Seventy three (82%) of the 
Salmonella isolated from retail meats purchased in the Washington D.C area displayed 
resistance to at least one antimicrobial.  Resistance to tetracycline (68%), streptomycin 
(61%), and sulfamethoxazole (42%) was most often observed whereas resistance to β -
lactams was less frequently observed (Table 1).  Among β-lactams, resistance was highest 
to ampicillin (29%) followed by cephalothin (24%), amoxicillin-clavulanate (21%), 
ceftiofur (19%), cefoxitin (18%), and ceftriaxone (9%). In addition to eight isolates 
resistant to ceftriaxone, nine isolates (10%) displayed intermediate susceptibility to 
ceftriaxone.  All the Salmonella that were intermediately susceptible to ceftriaxone were 
resistant to other β-lactams tested. The Salmonella also exhibited resistance to 
chloramphenicol (11%), kanamycin (6%), and gentamicin (2%). All Salmonella
recovered from retail foods in the Washington DC area were susceptible to amikacin, 
apramycin, ciprofloxacin, and nalidixic acid (Table 3-1).
Twenty eight (64%) Salmonella isolates from China displayed resistance to at 
least one antimicrobial. The highest frequencies of resistance were for tetracycline (43%), 
ampicillin (39%), and streptomycin (32%). Resistance was also observed, but to a lesser 
extent, for chloramphenicol (20%), sulfamethoxazole (16%), kanamycin (11%), and 
trimethoprim (9%) (Table 1). None of the isolates displayed resistance to β-lactams other 
than ampicillin, except for one isolate that was resistant to cephalothin. In contrast to the 
US isolates, approximately one third of the isolates from China were quinolone-resistant.  
Fourteen (32%) of the isolates were resistant to nalidixic acid, concomitant with 
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increased MICs for ciprofloxacin. The MIC90 for ciprofloxacin in the isolates from China 
was more than 30 times higher (0.5 µg/ml) than that of the isolates from the United States 
(<0.015) (data not shown).
Antimicrobial resistance genes and class 1 integrons. Among the 30 multiple-
antimicrobial-resistant Salmonella isolates (defined as resistant to two or more 
antimicrobials), 19 resistance genes conferring resistant to to six categories of 
antimicrobials, including β-lactams, aminoglycosides, phenicols, tetracycline, 
trimethoprim, and sulfonamides, were identified. The PCR results were consistent with 
the antimicrobial susceptibility phenotypes (Table 3-3). For example, the sulI and/or sulII
genes were detected in each of the sulfonamide-resistant Salmonella isolates; the tetA
and/or tetB genes were detected in each of the tetracycline-resistant isolates; and the 
dihydrofolate reductase genes, dhfr1, dhfr12, dhfr13, were detected in each of the 
trimethoprim-resistant isolates. Either or both of chloramphenicol acetyltransferase 
genes, cat1 and cat2, were detected in the chloramphenicol-resistant Salmonella isolates 
from China, while the flo gene was detected in each of the chloramphenicol-resistant 
Salmonella isolated from the United States. 
The distribution of aminoglycoside resistance genes in the Salmonella isolates 
was diverse. Six different resistance genes, aadA1, aadA2, aacC2, Kn, aph(3)-IIa, and 
aac(3)-IVa, were detected. The aadA1 gene was most frequently detected, being present 
in 17 of the isolates. Three isolates contained  aadA1 and aadA2. Isolate CHS31 
contained four types of aminoglycoside resistance genes, aadA1, aadA2, aacC2, and 
aac(3)-Iva.  A total of 12 antimicrobial resistance genes were amplified from the DNA of 
this isolate. The aac(3)-IVa, aacC2 genes, (conferring resistance to gentamicin), and the 
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Table 3-3.  Antimicrobial resistance and resistance gene profiles










blaCMY2, blaTEM1, aadA1, dhfr1, sulI, sulII, tetA 1.2kb
1163 b Agona Turkey Str-Sul-Tet aadA1, sulI, tetB 1.0kb
1271 b Djugu Pork Sul-Tri dhfr12, dhfr13, sulI, 2.0kb
S34 c H:E-2 Chicken Amo-Amp-Cef-Cep-Fox blaCMY2,  
S14 c, 
S14b 
Hadar Turkey Sul-Tet sulI, sulII, tetA
1272 b Heidelberg Pork Kan-Str-Sul-Tet aadA1, sulI, tetB   1.0kb
S31 c Infantis Chicken Amo-Amp-Cef-Cep-Fox blaCMY2
S33 c Infantis Chicken Amo-Amp-Cef-Cep-Fox-Sul blaCMY2,  sulI
S16 c Orion Pork Sul-Tet sulI, sulII, tetA





pse-1, flo-1, aadA2, aadA1,  sulI, sulII, tetA, 
tetB
1.0kb
S27 , S29 c Typhim. Chicken Amo-Amp-Cef-Cep-Fox blaCMY2






pse-1, flo-1, aadA2, aadA1,  sulI, sulII, tetA, 
tetB
1.0kb














blaCMY2, blaTEM1, flo-1, aadA1, sulII, tetA 2.7kb
CHS34 d Derby Pork Amp-Cml-Tri-Sul-Tet blaTEM1,cat1, cat2, dhfr1, sulI, tetA 1.5kb
CHS36d, 
CHS38 d
Derby Beef Amp-Cml-Str-Tri-Sul-Tet blaTEM1, cat1, cat2, aadA1, dhfr1, sulI, tetA 1.5kb
CHS32 d Derby Pork Amp-Cml-Kan-Nal-Str-Tet blaTEM1, cat2, aph(3)-IIA, aadA1, sulI, tetA
CHS5c d Enteritidis Chicken Amp-Str-Sul-Tet blaTEM1, aadA1,  sulII, tetA
CHS14 d Enteritidis Chicken Nal-Str-Sul-Tet aadA1, sulI, sulII,  tetA
CHS45 d Enteritidis Chicken Amp-Cml-Kan-Nal-Str-Tet blaTEM1, cat2, aph(3)-IIA, tetA
CHS43 Haardt Chicken Amp-Cml-Kan-Nal-Str-Tet blaTEM1,  cat2, aadA1, aph(3)-IIA, tetA 1.5kb
CHS31 d Typhim. Beef
Amp-Cef-Cml-Gen-Kan-Nal-Str-Tri-
Sul-Tet
blaTEM1, cat1, cat2, aadA2, aadA1,  aac(3)-IVA, 





Chicken Amp-Cml-Kan-Nal-Str-Tet blaTEM1, cat2, aadA1, aph(3)-IIA, tetA 
a. Amo, amoxicillin / clavulanic acid; Amp, ampicillin; Cef, ceftiofur; Cet, ceftriaxone; Cep, cephalothin; Fox, cefoxitin; Cml, 
chloramphenicol; Gen, gentamicin; Kan, kanamycin; Nal, nalidixic acid; Str, streptomycin; Sul, sulfamethoxazole; Tet, tetracycline; 
Tri, trimethoprim / sulfamethoxazole. b. Salmonella isolated in US from Jun. to Spt. 1998.  c. Salmonella isolated in US from Aug. 
1999 to Aug.2000. d. Salmonella isolated in China from Oct. 1999 to Dec. 2000
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aph(3)-IIa gene conferring resistanct to kanamycin were detected in Salmonlella .isolates 
from China. 
Three kinds of β-lactamase genes were detected in the Salmonella isolates. The 
blaCMY-2 gene was detected in 10 ESBL-resistant Salmonella, 5 of which also contained a 
blaTEM-1 like gene. Each of the nine ampicillin-resistant isolates from China contained a 
blaTEM-1 like gene. Consistent with previous findings (113), the blaPSE-1, which was 
located in a 1.0 kb class 1 integron, was amplified in each of two S. Typhimurium DT104 
isolates with the ACSSuT antibiogram (Table 3-3). 
Six integron amplicons, with sizes of 0.75kb, 1kb, 1.2kb, 1.5kb, 2.0kb and 
2.7kb, were detected in 16 (54%) of the 30 Salmonella isolates (Table 3-3). The most 
common antimicrobial resistance genes carried by these integrons were aadA1 and aadA2 
conferring resistance to streptomycin, and dhfrXII conferring resistance to trimethoprim. 
A 2.7kb integron in two S. Typhimurium DT208 isolates had an aadA gene as well as a 
1.2kb  gene of unknown function (GenBank accession # AY204504).  A protein BLAST 
search revealed that the 1.2kb open reading frame (ORF) shared 56% amino acid 
homology with a reverse transcriptase from Serratia marcescens.  No change in 
antimicrobial susceptibility was observed when this ORF was over-expressed as a cloned 
copy in E. coli (data not shown). 
Conjugative transfer of resistance genes.  Each of the 10 Salmonella isolates 
from retail meats purchased in the Washington D.C. area transferred their plasmids to E. 
coli at rates ranging from 6.0×10-8 to 2.4×10-4 transconjugants per recipient cell.
Examples of the conjugation study results are shown in Table 4. However, it is important 
to note that because the experiments were done with an excess of donor to recipient cells, 
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the efficiency of conjugation may have been constrained by the number recipient cells. 
Transconjugants 1083/1003 and 1290/1003 acquired resistance to 9 and 11 of the 
antimicrobial agents tested, respectively.  Transfer of blaCMY-2 and blaTEM-1 -like genes to 
the recipient E. coli strain was confirmed by PCR assay.  Because antimicrobial 
resistance genes specifying the ACSSuT resistance phenotype have integrated into the 
Salmonella chromosome (22, 24), the two S. Typhimurium DT104 isolates did not 
transfer this phenotype to the E. coli recipient strain (Table 3-4). One of four Salmonella 
from China transferred the ampicillin resistance phenotype to E. coli 1016. The transfer 
of other resistance phenotypes could not be measured because E. coli 1016 had these 
phenotypes prior to the conjugation experiment (Table 3-4).  
Discussion
In this study, we examined Salmonella isolates recovered from retail meats 
purchased in the United States and China for antimicrobial susceptibility phenotypes and 
genotypes.  In general, the findings are similar to those described in previous studies, 
showing that Salmonella in retail meats were commonly resistant to multiple 
antimicrobials, including tetracycline, sulfamethoxazole, and streptomycin (120, 231).
Our findings also showed that frequencies of antimicrobial resistance among Salmonella 
isolated from retail meats purchased in China were lower compared to those from the 
United States. Further studies involving larger sample sizes are required to more precisely 
determine if differences in antimicrobial resistance exist between Salmonella from the 
two countries.
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Table 3-4. Antimicrobial susceptibility profiles of donors, recipients, and transconjugants in the conjugation experimentsa
Strains Designation MIC (µg/ml) Conj. Resis.
Fox Cml Tet Cet Amo Cip Gen Nal Cef Sul Cep Tri Kan Amp Str Rate Genes
E. coli (1003) Recipient 4* 8 < 4 <0.25 1/0.5 >4 0.5 >32 0.25 16 8 0.12 <16 2 32
1083b Donor >16 < 4 >32 >64 >32/16 < 0.01 1 <4 8 >512 >32 >4 <16 >32 >64
blaCMY-2,
blaTEM-1







Donor >16 >32 >32 32 >32/16 < 0.01 16 <4 >8 >512 >32 <0.12 >64 >32 >64
blaCMY-2,
blaTEM-1







Donor < 0.5 >32 32 <0.25 16/8 < 0.01 < 0.25 <4 0.25 >512 4 0.25 <16 >32 >64
1275/1003 Transconjugant 2 2 < 4 <0.25 16/8 4 0.5 >32 0.25 >512 2 0.25 <16 2 >64
6.0 
x10-8
DT104c (S21) Donor 2 >32 >32 <0.25 16/8 < 0.01 < 0.25 <4 0.25 >512 4 <0.12 <16 >32 >64
S21/1003 Transconjugant 2 2 < 4 <0.25 16/8 4 0.5 >32 0.25 16 2 <0.12 <16 2 >64
6.0 x 
10-8
E. coli (1016) recipient 4 >32 >32 <0.25 1/5 0.25 >16 >32 0.25 >512 8 >4 >64 4 >64
CHS5d Donor 2 4 >32 <0.25 8/4 < 0.01 < 0.25 <4 0.25 >512 8 0.25 <16 >32 >64 blaTEM-1




a. Amp, ampicillin; Cef, ceftiofur; Cet, ceftriaxone; Cep, cephalothin; Cip, ciprofloxacin; Fox, cefoxitin; Cml, chloramphenicol; Gen, gentamicin; Kan, 
kanamycin; Nal, nalidixic acid; Str, streptomycin; Sul, sulfamethoxazole; Tet, tetracycline; Tri, trimethoprim / sulfamethoxazole. Resistance is indicated by 
boldface values.  b. Salmonella Agona.  c. Salmonella Typhimurium. d. Salmonella Enteritidis. *, MIC (µg/ml).
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Resistance to ceftriaxone is a concern because of its importance for the treatment
of salmonellosis in children. Ceftriaxone resistance in Salmonella is largely due to the 
AmpC β-lactamase (blaCMY-2) gene and has been increasingly reported in the United 
States (54, 231, 234).  Strains of Salmonella carrying blaCMY-2 were first isolated from 
humans, animal, and food samples in the United States in 1996 (54, 245) . In this study, 
19% of Salmonella isolates from retail meats purchased in the United States were 
resistant or intermediately susceptible to ceftriaxone and harbored the blaCMY-2 gene. 
Conversely, each of the Salmonella isolates from China was susceptible to ceftriaxone 
(and other cephalosporins), and none harbored blaCMY-2. A possible explanation for this 
observation is that ceftriaxone-resistant Salmonella in meats have arisen due to cross-
resistance between ceftriaxone and ceftiofur, a cephalosporin used in food animals (205, 
234). Ceftiofur, the only cephalosporin approved for therapeutic use in cattle, has been 
approved for use in the United States since 1988 whereas it was  approved for use in 
China in 2002 (www.agri.gov.cn/blgg/t20021219_36976.htm).
Quinolones and fluoroquinolones have been used in veterinary medicine in China 
since the 1980s. In contrast, they were not approved for therapeutic use in animals in the 
United States until 1995. The differences in fluoroquinolone susceptibility between the 
US and China isolates likely reflect the different approval dates in the two countries.  
Thirty-two of the Salmonella isolates from China were resistant to nalidixic acid and 
displayed increased MICs for ciprofloxacin, while each of isolates from the United States 
was susceptible to these drugs.  Nevertheless, the relatively high frequency of increased 
MICs for ciprofloxacin among the isolates from China warrants continued surveillance to 
detect emerging ciprofloxacin-resistant phenotypes.  
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Two S. Typhimurium DT104 strains (1275 and S21) isolated from pork within a 
one-year span in the Washington DC area displayed highly similar antimicrobial 
resistance phenotypes, genotypes, and PFGE patterns.  Both of these isolates had the 
classical ACSSuT resistance phentoype, and accordingly, were found to contain the 
blaPSE-1, flo-1, aadA2, sulI, and tetA genes.  These genes are known constituents of the 
Salmonella genomic island 1 (SGI1) multi-drug resistance (MDR) region (22, 144). In 
addition, three more resistance genes, sulII, aadA1, and tetB, were detected in these 
isolates, suggesting Salmonella may contain multiple genes that specify resistance to 
similar drugs (5, 9). In DT104, the resistance genes known as constituents of SGI1 were 
not transferred to E. coli, whereas the aadA1 gene specifying the streptomycin-resistant 
determinant is encoded in a conjugal plasmid, which can be transferred to E. coli by 
conjugation. In contrast to S. Typhimurium DT104, most of the antimicrobial resistance 
determinants in other Salmonella isolates were encoded in a transferable plasmid and 
could be transferred to E. coli by conjugation. Furthermore, the molecular mechanisms of 
antimicrobial resistance in these isolates were also different from SGI1 MDR in S.
Typhimurium DT104. The reason for widespread dissemination of SGI1 MDR among S.
Typhymurium DT104 is at present unclear.  
Most of the resistance genes, including blaCMY-2 and those contained in integrons, 
were located on plasmids in the Salmonella isolates in this study.  Plasmids carrying the
blaCMY-2 resistance were readily transferred under the selective pressure of β-lactam 
antibiotics; they were also co-transferred by selection with other antibiotics on the same 
plasmid (e.g., streptomycin). The E. coli recipient cells acquired 9 to 11 antimicrobial 
resistance phenotypes by receiving the plasmid from S. Agona and S. Typhimurium 
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DT208 via conjugation. These findings indicated that conjugal plasmids play a significant 
role in the dissemination of multiple-antimicrobial- resistant bacteria. 
Better understanding the molecular mechanisms by which antimicrobial resistance 
emerges and spreads should enable us in the future to design intervention strategies to 
reduce its progression. Because antimicrobial-resistant bacteria may be transferred to 
humans through the food chain (203, 236), selection of novel antimicrobial resistance 
mechanisms in Salmonella in animals (203), which specify resistance to  antibiotics used 
in humans, is troubling. Efforts including further implementation of HACCP programs in 
food production are needed to reduce the incidence of Salmonella in food. The judicious 
use of antibiotics, including cephalosporins and fluoroquinolones in food animals, is also 
critical to control the rapid spread of antimicrobial-resistant bacteria.  
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Chapter 4   Identification of Virulence and Antimicrobial-Resistant Genes in 
Salmonella and Escherichia coli using Microarray Analysis
Abstract
Characterization of antimicrobial resistance and virulence gene profiles provides 
important information of potential pathogenicity of bacterial pathogens. This 
information can in many instances be used to facilitate effective treatment of bacterial 
diseases. We developed and tested a PCR-based microarray analysis for detection of 
antimicrobial resistance and virulence genes in Salmonella and Escherichia coli. 
Twelve Salmonella and seven E. coli isolates were screened for the presence of 23 
antimicrobial-resistance genes and 25 virulence genes. Consistency between 
antimicrobial resistance phenotype and genotype was observed for each isolate. All 
isolates exhibiting resistance to third generation cephalosporins harbored blaCMY-2 and 
blaTEM-1. The aadA, tetA, and sulI genes were most commonly detected in bacteria 
resistant to streptomycin, tetracycline and sulfonamide, respectively. All S. 
Typhimurium DT104 isolates harbored virulence plasmids. E. coli O157 isolates 
harbored virulence genes typical of enterohemorrhagic E. coli (EHEC); serotype O126 
isolates harbored virulence genes typical to enteropathogenic E. coli (EPEC); and 
serotype O111, O78 and O147 isolates harbored virulence genes typical of 
enterotoxigenic E. coli (ETEC). Microarray analysis is an effective method to rapidly 
screen pathogenic strains of Salmonella and E. coli for multiple antimicrobial 
resistance and virulence genes. 
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Introduction
Salmonella spp. and diarrheagenic Escherichia coli are important causes of food-
borne diseases in the United States (128). The virulence of the former are mediated by 
gene clusters, including Salmonella pathogenicity islands SPI1, SPI2 and SPI5 (5), and 
by virulence plasmids, which facilitate infection of deep tissue (75, 76). In E. coli, 
virulence mechanisms are encoded by various chromosomal and plasmid-borne genes, 
products of which include the heat-labile and heat-stable toxins (STs), Shiga toxin  
(Stx1 and Stx2), enterohemolysin, intestinal adherence factors, and pili (39, 137). 
These virulence factors are reliable indicators of bacterial pathogenesis and, as such, 
are valuable markers that can characterize clinical isolates (17, 137). PCR assays 
provide a relatively rapid screen for virulence factors, and they can be used with a 
variety of samples (38, 150, 188). Further, multiplex PCRs have been devised for 
detection of more than one gene (58, 220). The drawback of these and similar assays, 
however, is that they are for the most part limited in the number of genes that can be 
reasonably screened.  
Characterization of antimicrobial resistance genes is also a powerful tool for 
describing bacterial pathogens. For instance, it can be used to investigate the 
population dynamics of clinical isolates, including the spatial and temporal distribution 
of resistance genes (33, 132). Various methods, including DNA sequencing, DNA-
DNA hybridization, and PCR arrays, have been used to characterize antimicrobial 
resistance genes in bacteria (21, 33, 52, 132). Variant Salmonella genomic island multi-
drug resistance (MDR regions), have been used to characterize clinical isolates 
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belonging to Salmonella serovars Typhimurium DT104 and Agona (21). We recently 
used PCR technology to screen multiple-antimicrobial-resistant Salmonella from retail 
meats for the presence of 61 different resistance genes (33). Nevertheless, while these 
methods provide valuable genotypic information, they are time-consuming, expensive, 
and otherwise ill-suited for analyzing a large number of genes from multiple samples. 
DNA microarrays offer a viable alternative to PCR for genotypic characterization 
of bacteria. Microarrays have been used for detection of antimicrobial resistance genes 
(26, 227), characterization of virulence and pathogenecity, species determination (35, 
100), genome comparisons and detection of genetic polymorphisms (51, 91, 124). 
Prototype microarrays have been developed to detect erythromycin, tetracycline, and 
rifampin resistance determinants in clinical isolates (26, 195, 218), as well as virulence 
factors (35, 227). We describe a PCR product-based DNA microarray for 
characterization of antimicrobial resistance and virulence genes in Salmonella and 
diarrheagenic E. coli.  
Materials and methods
Bacterial isolates Isolates investigated in this study are shown in Table 4-1. All 
isolates were recovered from retail ground meat and food animals using methods 
described in the U.S. Food and Drug Administration Bacteriological Analytical Manual 
(1). The isolates were further identified with API identification kits (BioMerieux, Marcy, 
France) and serotyped with commercial antiserum (Difco, Detroit) according to 
manufacturers’ instructions. Susceptibilities to seventeen antimicrobials used in the 
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blaCMY-2, blaTEM-1, blaPSE-1, aadA,
aac(3)-IVA, tetA, dhfr1, sulI, sulII, 
Int, QacA





blaCMY-2, blaTEM-1blaaPSE-1, AADa, 
aac(3)-IVA, tetA, dhfr1, sulI, sulII, 
Int, QacA








blaCMY-2, blaTEM-1, aadA, aac(3)-IVA, 
tetA, tetB, flo, sulI, Int, QacA








blaCMY-2, blaPSE-1, aadA, aac(3)-
IVA, tetA, flo, sulI, Int, QacA






blaPSE-1, aadA, aac(3)-IVA, tetA, 
tetB, flo, cmlA, sulI, sulII, Int, QacA
spvR, spvC, sipA, sipB, 






blaPSE-1, aadA, aac(3)-IVA, flo, tetA, 
tetB, sulI, sulI, Int, QacA
spvR, spvC, sipA, sipB, 







blaTEM-1, blaPSE-1, aadA, aac(3)-IVA, 
aacC2, tetA, tetB, cat1, cat2, dhfr12, 
dhfr13, sulII, Int, QacA
spvR, spvC, sipA, sipB, 





blaCMY-2, blaTEM-1, aadA, aac(3)-IVA, 
tetA, tetB, flo, sulI, Int, QacA
sipA, sipB, sipC, invA, sop, 
fliC, pagC, ent
S09 Heidelberg Kan-Str-Sul-Tet
blaPSE-1, blaTEM-1, aadA, aphA, tetB, 
sulI, Int, QacA
spvR, spvC, sipA, sipB, 




blaCMY-2, blaPSE-1, aac(3)-IVA, 
aacC2, sulI, Int, QacA
sipA, sipB, sipC, invA, sop, 
fliC, pagC, ent
S11 Untypable Amp-Cml-Nal-Kan-Str-Tet
blaTEM-1, blaPSE-1, aadA, aac(3)-IVA, 
aphA, tetA, cmlA, sulI, Int, QacA
sipA, sipB, sipC, invA, sop, 
fliC, pagC, ent
S12 Haardt Amp-Cml-Nal-Kan-Str-Tet
blaTEM-1, aadA, aac(3)-IVA, tetA, 
cat2,  Int, QacA
sipA, sipB, sipC, invA, sop, 
fliC, pagC, ent
E01 O157 Cef-Cml-Nal  aac(3)-IvA, cmlA





blaCMY-2, blaTEM-1, blaPSE-1, aadA, 
aac(3)-IVA, aacC2, aphA, cmlA, 
sulII, Int, Qac,




blaCMY-2, blaTEM-1, blaPSE-1, aadA, 
aac(3)-IVA, aacC2, aphA, cmlA, 
sulII, Int, Qac,




blaTEM-1, aadA, aac(3)-IVA, cat1, 





blaTEM-1, blaPSE-1,  aadA, aac(3)-IVA, 
aacC2, tetA, , cmlA, dhfr13, sulII, 
Int, QacA




blaTEM-1, blapse-1, aadA, aac(3)-
IVA, tetA, cmlA, dhfr13, sulII
LT, Sta, astA,
E07 O147 Cml-Gen aac(3)-IVA ,cmlA,  Int, QacA LT, Sta
S, Salmonella; E, E. coli;  Amo, Amoxicillin / Clavulanic acid; Amp, Ampicillin; Cef, Ceftiofur; Cet, Ceftriaxone; Cep, 
Cephalothin; Fox, cefoxitin Cml, chloramphenicol;  Gen, Gentamicin; Kan, Kanamycin; Str, Streptomycin; Sul, Sulfamethoxazole; 
Tet, Tetracycline; Tri, Trimethoprim / Sulfamethoxazole Cip, ciprofloxacin
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National Antimicrobial Resistance Monitoring System (NARMS) were determined via 
National Committee for Clinical Laboratory Standards (NCCLS) guidelines for broth 
micro-dilution (139, 141). All susceptibility assays were done with the Sensititre 
Automated Antimicrobial Susceptibility System (Trek Diagnostic Systems, Westlake, 
Ohio). 
Microchip design and construction The design of the microchips used in this 
study is diagrammed in Figure 4-1. Genes included on the microchip are listed in Table 
4-2. Three general classes of genes were arranged on the microchip: (i) antimicrobial 
resistance genes, (ii) Salmonella virulence genes, and (iii) E. coli virulence genes. All 
these genes were amplified by PCR using forty-seven different primer sets targeting to 
23 antimicrobial resistance genes conferring resistance to: (i) β-lactams, (ii) 
aminoglycosides, (iii) chloramphenicols, (iv) tetracycline, (v) trimethoprim, (vi) 
macrolides, and (vii) sulfonamides , 12 E. coli virulence genes, 10 Salmonella virulence 
genes, and two positive control genes (E. coli and Salmonella gyrA gene). Briefly, PCR 
was performed in a total volume of 50 µl distilled H2O with 0.25mM of each 
deoxyribonucleotide, 1.5mM MgCl2, 0.2 U Gold Taq DNA polymerase, and 50 pmol 
each primer. The temperature profile included an initial template denaturation step at 
95ºC for 10 min, followed by 30 cycles of 95ºC for 30 s, 55ºC for 1 min, and 72ºC for 1 
min, and a final step at 72ºC for 7 min (8). The presence of class I integrons among the 
30 Salmonella  isolates was determined by PCR using primers 5’CS (5'-
GGCATCCAAGCACAAGC-3') and 3’-CS (5'-AAGCAGACTTGACTGAT-3') as 
previously described (244). All PCR products were purified with High PCR Purification 
kits (Roche) and sequenced at the Center of Agriculture Biotechnology, University of 
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                                      1        2        3         4         5       6    
Fig 4-1. Microchip design and construction. Each circle on the microchip represents one 
gene with four repeated spots. Genes included on the microchip are listed in Table 2. All 
genes were arranged into four distinct quadrants and these four quadrants were duplicated 
on the slides. The left two quadrants (Column 1-3, row A-F ) contained antimicrobial 
resistance genes and the right up quadrant (Column 4-6, row A-D)contained E. coli
virulence genes and right down quadrant (Column 4-6, row E-H) contained Salmonella











Table 4-2. Microarray design, gene location, gene functions and the primer sequence of antimicrobial-resistant and virulence genes
GL Genes Description Oligonucleotide sequence




TGG CCG TTG CCG TTA TCT AC      CCC GTT TTA TGC ACC CAT GA















A   
CTCGATGGCGACCGAGCTTCA
1C S gyrA Positive control ACGTATTGGGCAATGACTGG GGAGTCGCCGTCAATAGAAC






TCT CGG AGG GCG AAG AAT 
CT       





































AAA TTC CGG GTG AGC AGA 
AG      




GCA GTC GCC CTA AAA CAA 
AG     












CCT GTT TCG TCC GAC ACA GA       GAA GCG CAG CCG CAA TTC AT
































4C fliC H7 antigen GCGCTGTCGAGTTCTATCGAGC CAACGGTGACTTATCGCCATTCC
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5C rfbE





















4E spvR Virulence plasmid CGGAAGAATGGCACTCTTAT GAATGCAGGGTTGGTAATAC





6E sipA SPI1 component TACCCCTGCTGCTACGTAAT CTCCAGGGCTTTACGTATCA
4F sipB SPI1 component TGGCAGGCGATGATTGAGTC CCCATAATGCGGTTCGTTTC
5F SipC SPI1 component TGCCCTGGCAAATAATGTCA CATCGATTCGGGTCATATCC













AGC CCC TCT TCA CCA AAG AC       GCC GAT ACC TCC CAA CTG TA
5H ent Salmonella entrotoxin CATCGCACAGTACCAGATCA GATGCCCAAAGCAGAGAGAT
6H negative negative control
* Gene Location in microchips.
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Maryland, College Park, MD. Resultant DNA sequence data were compared to data 
in the GenBank database using the BLAST algorithm (7) via the National Center of 
Biotechnology Information’s web site (www.ncbi.nlm.nih.gov). 
 PCR products with the sizes ranging from 400 ~ 800bp were then quantified 
and diluted to a final concentration of 10 mg/ml after which 50 ul of each product 
were transferred to 96-well plates and printed onto CAST slides (Schleicher & 
Schuell, Keene, NH) using the Microcaster MicroArray system (Schleicher & 
Schuell). Antimicrobial resistance genes were spotted in duplicate on the left-most 
two quadrants of the chips and virulence genes from Salmonella and E. coli were 
spotted in duplicate on the two right-most.The average spot size was 500 µm. Printed 
slides were put on a sheet of GB002 paper saturated with 0.4N NaOH/3M NaCl (to 
denature the DNA) and neutralized by placement on GB002 paper saturated with 
0.5M Tris/1.5M NaCl. The slides were cross-linked to be immobilized under 20 
mjoules/cm2 UV light using GS GENE LINKERTM UV Chamber (Bio-Rad). They 
were then dipped in distilled water for 5 min, dried at room temperature, and stored 
at 4ºC until further use.
Detection of antimicrobial- resistant and virulence genes using microchip
Chromosomal and plasmid DNA from Salmonella and E. coli were isolated using 
Wizard Genomic DNA Purification kits (Promega, Madison WI) and High Plasmid 
Purification kits (Roche, Indianapolis IN), respectively.  Chromosomal and plasmid 
DNA were randomly amplified and labeled with digoxigenin (DIG) using the DIG-
High Prime Kit (Roche) according to manufacturer’s instructions. 
Labeled DNA was hybridized to microchips using a microhybridization kit 
(Schleicher & Schuell) according to manufacture’s instructions. Hybridized 
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microchips were then detected using the DIG Nucleic Acid Detection Kit (Roche). 
Briefly, after three post-hybridization washes, microchips were incubated in 100 ml 
blocking buffer solution at room temperature for 1 h. The microchips were then 
transferred to 20 ml blocking buffer supplemented with anti-DIG-AP conjugate and 
incubated for 1 h at room temperature. Next, the microchips were washed in buffer 
three times for 15 min at 42ºC. Lastly, microchips were incubated in 10 ml 
detection buffer supplemented with 4 ul AP substrate nitro blue tetrazolium/5-
bromo-4-chloro-3-indolyl phosphate (NBT/BCIP; Roche) for 5 min. Reactions were 
stopped by washing the slides the slides in distilled water, followed by storage in 
distilled water for two to three months. 
After hybridization, colorimetric images of processed microarrays were 
generated using the Gel-Doc 1000 system (Bio-Rad). DNA spots with densities that 
differed from the negative control at a statistical level of P<0.01 were considered 
positive for hybridization. 
Experimental controls Six genes, blaTEM-1, aadA, tetA, cat1, dhfrI, and LT
(Fig 1), which were amplified from E. coli CH4, and the hylA gene, which could 
not be amplified from CH4, were printed to CAST slides. All six genes that could 
be amplified by PCR resulted in positive hybridization. The gene which could not 
be amplified by PCR resulted in negative hybridization (Fig 4-2). 
Results and discussion
Each of the 19 multiple-antimicrobial-resistant bacterial isolates examined 
here (12 Salmonella and 7 E. coli) were successfully differentiated by their patterns 
of hybridization to virulence genes (Fig 4-3A, 4-3B). DNA from each of the isolates 
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Fig 4-2. Evaluation of the validity of Microarray methodology. The microarray for 
experimental control was constructed by printing blaTEM-1, aadA, tetA, cat1, dhfrI, and 
LT genes which were amplified from strain CHA4 and hlyA gene which could not be 
amplified from this isolate onto CAST slides. Each gene has three vertically-arranged 
repeated areas with nigh spots each area.  The arrangement of the genes on slide was 
seen in the following table.  CHA 4 showed positive hybridization to all genes which 
were successfully amplified in CHA4 by PCR and negative hybridization to hlyA 
which was not amplified by PCR and negative control. 
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Fig 4-3A. The hybridization of S04 to microarray, The figure presented half of the 
slides without duplication. The microarray was designed as seen in Fig 1 and table 2. 
S04 showed positive hybridization to blaCMY-2, blaTEM-1, aac(3)-Iva, Salmonella gyrA, 
E. coli gyrA, tetA, tetB, flo, cmlA, sulI, int, qacA, sipA, sipB, SipC, invA, sop, fliC, 
pag, ent. 
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Fig 4-3B. The hybridization of E03 to microarray, The figure showed half of the 
slides without duplication. The microarray was designed as seen in Fig 1 and table 2. 
E03 showed positive hybridization to blaCMY-2, blaTEM-1, blaPSE-1, aadA, AAC(3)-IvA, 
aacC2, Salmonella gyrA, E. coli gryA, tetA, cmlA, sulII, int, qac, LT, ST, VT1, hlyA, 
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positively hybridized to the gyrA genes which were positive control for all 
Salmonella and Ecoli isolates. DNA from the Salmonella isolates hybridized to 
Salmonella-specific virulence genes whereas DNA from the E. coli isolates 
hybridized to E. coli-specific virulence genes (Table 4-1). Four of 12 Salmonella 
isolates, including all of three S. Typhimurium DT104 and one S. Heidelberg showed 
positive hybridization to spvR and spvC. These two genes were carried on the 
Salmonella virulence plasmid, which is known to be required for the efficient 
infection of deep tissues by this pathogen (75, 76). Each of the Salmonella isolates 
identified in this study harbored virulence genes encoding SPI1, SPI5, and other 
virulence factors such as pagC. These genes encoded Salmonella major virulence 
factors which enable Salmonella to invade host cells, induce enteropathogenicity 
(diarrhea), and promote survival in macrophage (4, 179, 199) . 
S. Typhimurium DT104 is recognized as a serious public health concern. S. 
Typhimurium DT104 can cause severe illness and is usually resistant to ampicillin, 
chloramphenicol, streptomycin, sulfornamides, and tetracycline (175). The number 
of cases of infection with serotype typhimurium DT104 has increased in many 
countries (27, 95, 121). Each of the three S. Typhimurium DT104 isolates identified 
in this study showed positive hybridization to spvC and spvR genes of virulence 
plasmids, whereas none of S.Typhimurium DT208 isolates showed positive 
hybridization to these genes (Table 4-1). Furthermore, each of the S.Typhinurium 
DT104 isolates were also found to harbor sipA, sipB, SipC genes (which are SPI1 
components),  invA (responsible for Salmonella invasion of host tissue), sop  (a 
component of SPI5), fliC (the flagella filament protein), pagC (the survivor 
promoter)  and ent (Salmonella enterotoxin) (5). Although the number of strains 
studied was relatively few, these results give preliminary evidence suggesting the 
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presence of virulence genes and plasmids may be a valuable marker for rapid 
identification of S. Typhimurium DT104. 
The microarray assay also proved useful for differentiating pathogenic strains 
of E. coli. Isolates of serotype O157 harbored virulence genes characteristic of 
EHEC, including stx1, stx2, hylA, eseA, fliC and rfbE. Those of serotypes O111, 
O78 and O147 showed positive hybridization genes encoding LT and ST, which are 
the typical virulence products associated with ETEC. Serotype O78 was avian 
pathogenic E. coli and typically possessed virulence factors such as temperature
sensitive hemagglutination (TSH), and increased serum survival factor (ISS). In 
addition to these virulence factors, O78 possessed virulence factors typical of 
EHEC and ETEC, which may contribute the pathogenicity of O78 (57, 130). 
Serotype O126 hybridized to aefP, bfp and astA, the typical virulence genes of 
EPEC (Table 4-1). In addition to typical ETEC virulence genes, isolates of 
serotypes O111 and O78 possesed stx1 and hlyA genes, which are major virulence 
factors found in EHEC. Several studies have reported that some classical EPEC and 
ETEC carried stx gene suggesting that EHEC groups of pathogenic E. coli have 
evolved from other pathogenic E coli through acquiring of stx system (184). 
Nevertheless, these data suggest microarray analysis was a useful tool for rapidly 
identifying and differentiating diarrheagenic E. coli into pathogenic subgroups, 
which in turn could be used to help guide treatment choices. 
It is well understood that continued emergence of antimicrobial resistance 
among bacterial pathogens constitutes a serious public health threat. Data presented 
here indicate microarray analysis can be used to rapidly identify the genetic 
underpinnings of resistant strains. We observed that the most of the antimicrobial 
resistance phenotypes of the bacteria identified in this study correlated with their 
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hybridization genotypes (Table 4-1). For example, each of the isolates observed to 
be resistant to third-generation cephalosporins also harbored the blaCMY-2 and 
blaTEM-1 genes. In the United States, the former of these two genes has been 
implicated in emergence of S.Typhimurium strains resistant to expanded-spectrum 
β-lactams, as well as AmpC-multi-drug-resistant strains of S. Newport (55, 143, 
171, 230). 
Among the β-lactam-resistant isolates, two E. coli isolates, E03 and E04, and 
two Salmonella isolates, S01 and S02, harbored blaPSE-1 other than blaCMY-2 and 
blaTEM-1 genes.  Salmonella isolate S09, which was susceptible to ß-lactam 
antibiotics, showed hybridization to blaPSE-1; however, PCR with blaPSE-1-specific 
primers failed to amplify blaPSE-1 in this isolate (data not shown). We thus reasoned 
that either this isolate contained either (i) a gene with high homology to balPSE-1 or 
(ii) a silent ß-lactamase gene. E. coli isolate E01 was found resistant to cephalothin, 
but it did not hybridize to any of the three ß-lactamase genes tested. It is reasonable 
to suggest that this isolate may have contained a ß-lactamase different from those 
included in this study.
All streptomycin-resistant isolates harbored the aadA gene; all tetracycline-
resistant isolates harbored tetA, tetB, or both; and all sulfonamide-resistant isolates 
harbored the sulI and/or sulII genes. Consistent with recent findings (33) the cat1
and flo genes were most frequently detected in chloramphenicol-resistant E. coli
and the cmlA gene was most frequently detected in chloramphenicol-resistant 
Salmonella.
The microarray was also useful for identifying integrons among Salmonella 
and E. coli. The int and qac gene cassettes are hallmark features of class I integrons 
(177). With the exception of two Salmonella isolates, each of the int- and qac-
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positive isolates contained class I integrons ranging in size from 1 to 2.7 kb. The 
presence of class I integrons among these isolates suggests they may have played a 
role in the dissemination of antimicrobial resistance genes. Regarding the two 
Salmonella isolates that contained the int and qac cassettes, but in which class I 
integrons were not detected, we offer two explanations. First, the isolates may have 
contained integrons of a size that could not be amplified by regular PCR. For 
instance, long-range PCR is known to be more effective than regular PCR for 
amplification of integron cassettes longer than 3 kb (117). Second, the isolates may 
have contained integrons devoid of gene cassettes. Further investigation is 
underway.   
Two S.Thyphimurium DT104 strains with classical ACSSuT resistant 
phenotypes harbored the blaPSE-1, flo, aadA, sulI, and tetA genes. These genes are 
known constituents of the SGI1 MDR region of S.Typhimurium DT104 (21, 52). In 
addition, these two isolates contained tetB and sulII genes as well. Another 
S.Typhimurium DT104 showed positive hybridization to twelve different 
antimicrobial-resistant genes. The aac(3)-IVA gene, previously shown to confer 
resistance to gentamicin (180), was hybridized by all the bacterial isolates, 
regardless of whether gentamicin-resistant or susceptible; the PCR assay specific to 
aac(3)-IVA failed, however, to amplify the gene from all of isolates. The positive 
hybridization of aac(3)- IVA to all the isolates indicated that there may have some 
Salmonella and E. coli chromosomal genes which showed high homology to 
aac(3)-IVA. The failure to amplify aac(3)- IVA from gentamicin-resistant bacteria 
suggested that resistance determinants other than those included on the microchips 
were responsible for the observed gentamicin-resistant phenotypes. 
 We conclude that the PCR-based microarray can be used as an efficient and 
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rapid method to screen the genotypes Salmonella and diarrheagenic E. coli for 
multiple antimicrobial resistance and virulence genes. Moreover, this method can be 
used to screen a large number of isolates. The method developed here has potential 
clinical significance in that by rapidly and accurately providing information about 
virulence mechanisms and antimicrobial resistance patterns, it can help guide 
disease treatment for infections caused by these important foodborne pathogens.
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Chapter 5 The Role of Target Gene Mutation and Efflux Pump in 
Fluoroquinolone-Resistant Salmonella
Abstract
Increasing resistance to antimicrobial agents that are important in the treatment 
of human diseases, such as fluoroquinolones (FQ) for the treatment of Salmonella, has 
significant public health implications. The mechanisms involved in fluoroquinolone 
resistance in Salmonella include target alterations and overexpression of efflux 
pumps. The present study evaluated known and predicted efflux pumps that are 
associated with FQ resistance and the interactive role that target gene mutations and 
efflux pumps play in FQ resistance. S. Typhimurium strains S21 and PY1 were in 
vitro induced to be FQ-resistant via step wise selection on increasing concentrations 
of ciprofloxacin. The wild type Salmonella isolate and four different level 
fluoroquinolone-resistant mutants with ciprofloxacin minimum inhibitory 
concentration (MIC) = 0.25, 4, 32, 256 ug/ml were selected. The expression of efflux 
pump genes acrA, acrB, acrE, acrF, emrA, emrB and tolC were significantly 
increased among the FQ-resistant mutants using quantitative RT-PCR. The expression 
of yegO, yegN, and emrD was also detected among mutants with higher ciprofloxacin 
MICs. Deletion of acrAB or tolC in Salmonella S21, Spy1 and their mutants resulted 
in increased susceptibility to FQ and other antimicrobial classes including 
chloramphenicol, tetracycline, β-lactams and trimethoprim. The replacement of 
mutated gyrA of all FQ-resistant mutants with wild type allele gyrA+ also 
significantly increased the susceptibility to FQ, whereas the replacement of parC with 
parC+ did not. Similar results were also observed among field isolates of 
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ciprofloxacin- or nalidixic acid-resistant Salmonella when acrAB or tolC was deleted, 
or gyrA or parC was replaced. Our findings show that the combination of mutations in 
gyrA and upregulation of the AcrAB efflux pump were the primary mechanisms 
associated with fluoroquinolone resistance in Salmonella. It appears that 
overexpression of the AcrAB-TolC efflux pump enables Salmonella to be tolerant to 
low levels of FQ and target gene mutations occur subsequently under further FQ 
selective pressure. The continuous overexpression of AcrAB-tolC efflux conferred 
high FQ resistance in Salmonella.
Introduction
Quinolone-resistant Salmonella has emerged in humans and animals in the past 
few years and spread worldwide. However, high-level fluoroquinolone resistance is 
not frequently encountered in Salmonella spp, although it was suggested that 
fluoroquinolone-resistant Salmonella strains could be counterselected in the field (67). 
High-level fluoroquinolone-resistance Salmonella has been firstly reported in S.
Typhimurium DT204 during the early 1990s in Germany (86). More recently, three 
nosocomial outbreaks of fluoroquinolone-resistant Salmonella infections have been 
reported in the United States, Taiwan and Japan (34, 149). The resistance to 
fluoroquinolone in Salmonella is increasing recently, based on the report from 
National Antimicrobial Resistance Monitoring System (NARMS). The emergence of 
fluoroquinolone resistance in Salmonella threatens human health because 
fluoroquinolones are commonly used to treat invasive Salmonella infections in
humans (145, 224). It is very important and really needed to study the mechanisms of 
fluoroquinolone resistance in Salmonella because the understanding of molecular 
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mechanisms by which the antimicrobial resistance emerges and spreads should enable 
us to design strategies to intervene or stop or arrest the progress. 
Bacterial resistance to fluoroquinolone is usually mediated by removing the 
drug by active efflux pump and development of mutations in the target of 
fluoroquinolone action (bacterial gyrase and topoisomerase IV).  Within GyrA of E. 
coli, mutations of two amino acids, serine 83 and aspartic acid 87 are most commonly 
detected. A single mutation in each site confers resistance to nalidixic acid (226, 242). 
When both sites are mutated, the level of resistance can be three or fourfold higher 
than a single mutation, which can confer the resistance to ciprofloxacin (12, 201, 208, 
216). Mutations in ParC are only detected in GyrA mutants and always with high 
fluoroquinolone resistance. Topoisomerase IV mutations do not by themselves confer 
resistance. These findings suggested that GyrA is the primary target in E. coli, 
whereas ParC is as the secondly target. Mutations in GyrB could be found in both 
high and low quinolone resistance isolates. GyrB mutations in clinical isolates are 
analyzed in two specific sites, Asp426 and Lys 447 in E. coli (240). Recent crystal 
structure of yeast topoisomerase IV demonstrated a quinolone-binding pocket around 
the active site for DNA cleavage. GyrB might be part of the quinolone-binding 
pocket. The homologous gene for topoisomerase IV, ParE , can also display resistance 
mutations. 
In Salmonella, single mutations in GyrA, Ser83 or Asp87, are identified in 
quinolone-resistant isolates recovered from humans and animals (78, 159, 172). 
Mutations in both Ser83 and Asp87 in GyrA are detected in ciprofloxacin-resistant 
Salmonella isolates from humans and animals (34, 85, 156). Mutations in ParC, Ser80
or Gly78, has recently reported in ciprofloxacine-resistant human isolate and 
laboratory induced isolates. Mutations in GyrB have also been found, with a 
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substitution of Ser464 revealed in one clinical isolate. Introducing into the respective 
mutants the corresponding plasmid-coded quinolone-susceptible allele of either E. 
coli gyrA, gyrB, or parC resulted in reduction of quinolone resistance, indicating a 
role for these mutations in quinolone resistance. No mutations in ParE have yet been 
described in quinolone-resistant Salmonella strains (88). 
Efflux pumps are membrane transport proteins involved in the extrusion of toxic 
substrates (including antibiotics) from within cells into the external environment. In 
the prokaryotic kingdom there are five major superfamilies of active drug efflux pump 
transporters: ATP-binding cassette (ABC), major facilitator superfamily (MFS), small 
multidrug resistance (SMR), multi antimicrobial resistance (MAR), resistance 
nodulation division (RND) and multidrug and toxic compound extrusion (MATE)
(210). Genome sequences analyses of prokaryotic microorganisms with available 
complete sequence revealed that about 5~10% of all bacterial genes are involved in 
transport, and that a large proportion of these genes encode efflux pumps. Antibiotic 
efflux pumps appear a major component of microbial resistance to many classes of 
antimicrobial agents (210). In many cases, efflux pump genes are within an operon, 
with a regulatory gene controlling their expression. Increased expression of efflux 
pump genes is associated with the resistance to substrates including antibiotics. 
Overexpression of efflux pump genes can result from mutations within local repressor 
gene or may result from activation of a regulon regulated by a global transcriptional 
regulator such as MarA or Sox (127, 169). For at least four of antibiotics, namely 
tetracycline, macrolide, chloramphenicol, and fluoroquinolone, antibiotic efflux 
pumps appear to confer medium or high level of antibiotic resistance, defeating 
medically applicable treatments of the corresponding infections with these 
antimicrobial agents (16, 111, 147, 161, 166).
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Efflux pumps that contribute to antibiotic resistance have been described from a 
number of clinically important bacteria other than Salmonella, including 
Campylobacter jejuni (CmeABC ), E. coli (AcrAB-TolC, AcrEF-TolC, EmrB, 
EmrD), Pseudomonas aeruginosa (MexAB-OprM, MexCD-OprJ, MexEF-OprN and 
MexXY-OprM), Strepotococcus pneumoniae (PmrA), Staphylococcus aureus (NorA)
(156). An antibiotic efflux pump that has been described in Salmonella is an AcrAB-
TolC system where AcrB is an efflux protein in the cytoplasmic membrane and AcrA
is an accessory protein, linking AcrB with the outer membrane protein TolC (68, 
160). Overexpression of AcrAB-tolC is mediated by the overexpression of 
transcriptional activators MarA and SoxS, which are regulated by MarR and SoxR 
proteins (6, 169). The overexpression of MarA and SoxS adversely regulates OmpF, 
an outer membrane pore forming protein. The net result is that the OmpF is less 
expressed and less drugs is able to enter the cell, that the AcrAB is overexpressed and 
more drugs were effluxed from cell. Other efflux pumps have not yet been studied in 
Salmonella. The objectives of this study are to determine the molecular mechanisms,
including efflux pumps and gyrase and topoisomerase IV gene mutations, of 
fluoroquinolone resistance in Salmonella. 
Materials and methods
Bacterial strains Salmonella Typhimurium S.py1 (14028s) was an ATCC 
standard strain and Salmonella Typhimurium S21 was a field strain isolated from 
meat product. S. Typhimurium CS1, CS3, CS9 isolated from diseased animals were 
resistant to ciprofloxacin and S. Typhimurium CHS14, CHS18, CHS38 isolated from 
meat products were resistant to nalidixic acid but susceptible to ciprofloxacin. 
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Selection of nalidixic acid and ciprofloxacin-resistant mutants in vitro The 
selection of nalidixic acid and ciprofloxacin-resistant Salmonella mutants was 
performed as described by Heisig (84) with modification. Briefly, Salmonella strains 
susceptible to nalidixic acid and ciprofloxacin were grown in brain heart infusion 
(BHI) broth (Difico Detroit, MI) at 37°C overnight. The overnight culture was spread 
on Mueller Hinton agar (MHA) plates (Difico) supplemented with 4µg/ml nalidixic 
acid and incubated for 24-48h at 37ºC. Single colonies were selected and incubated in 
BHI supplemented with the same concentration of the antibiotic as in MHA plates. 
The overnight culture was spread on MHA plates supplemented with 2X 
concentration (8µg/ml) of nalidixic acid as that in BHI broth. Similar selections were 
repeated in 4X, 8X and higher concentrations of antibiotics. Mutants selected from 
128µg/ml nalidixic acid plates were then exposed to ciprofloxacin at concentrations 
ranging from 0.5µg/ml to 128µg/ml. The in vitro selection procedures were similar as 
those for nalidixic acid resistance. The mutants from each stage were stored in –80°C 
freezer until further study. 
Identification of multiple-drug resistance efflux pump genes In order to 
conduct a comprehensive investigation of the role of multidrug efflux pump on 
susceptibility to fluoroquinolone in Salmonella, 12 multidrug efflux pump genes 
belonging to super families of ABC, MFS, RND, SMR, and MATE were selected for 
use (Table 5-1). These genes included known and predicted efflux pump that were 
identified by bioinformatics analysis as described by Paulsen et al (152, 153). Except 
for AcrAB, all other efflux pump genes were predicted or had been identified to 
encode a fluoroquinolone or multidrug efflux pumps in other Gram  negative 
organisms such as E. coli. 
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Table 5-1. Known and predicted Salmonella efflux pumps and regulatory genes
Salmonella Assigned Genebank # Functions Genetic 
Efflux pumps  families Context
MarA ae008766 regulation marA
SoxS ae008750 regulation soxS
TolC OMP ae008846 putative out membrane protein tolC
MdlB ABC ae008717 MDR like ATP-binding protein mdlB
EmrB MF ae008828
translocase substance of light 
hydrophobicity
emrB
EmrD MFS ae008877 multidrug pump emrD
AcrA MFS ae008717 transmembrane acrA
AcrE MFS ae008856 membrane acrE
EmrA MFS ae008828 MDR secetion protein emrA
YdhE MATE ae008762 putatative transport protein ydhE
AcrB RND ae008717 multidrug efflux pump acrB
AcrF RND ae008856 envelop formation acrF
YegN RND ae008794 acrifluvin resistance protein D yegN
YegO RND ae008794 acrifluvin resistance protein E yegO
ABC, ATP-binding cassette; MFS,major facilitator superfamily; SMR, small 
multidrug resistance; MAR, multi antimicrobial resistance; RND, resistance 
nodulation division; MATE, multidrug and toxic compound extrusion.
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Determination of efflux pump gene expression level The efflux pump gene 
expression level was determined by RT-PCR. Briefly, total RNA was extracted from 
Salmonella using the RNeasy Kit (Qiagen Inc, Valencia CA) and then treated with 
DNA-free kit (Ambion, Austin TX) to remove DNA contamination according to the 
manufacturer’s instructions. The concentration of the RNA was measured using 
Smartspect 300 (BioRad, Hercules, CA ) and 1µg of the total RNA was used in RT-
PCR reactions. The RT-PCR was performed using Access RT-PCR system (Promega, 
Madison, WI ) following the manufacturer’s instructions. The RT-PCR reaction was 
carried out in a 50µl reaction containing 10× RT-PCR buffer, 2.0mM MgSO4, 0.2mM 
each dNTP, 50pmol each primer (Table 5-2), each of 0.1u/µl Tfl DNA polymerase 
and AMV reverse transcriptase. One-step RT-PCR was performed in thermal cycler 
(GenAmp PCR System 9600, Perkin Elmer) by incubating at 48ºC for 45min, then 
denaturing at 94ºC for 2min, following by 25 cycles at 94ºC for 30sec, 60ºC for 1min, 
68ºC for 2min, then incubating at 68ºC for 7min. RT-PCR products were quantified in 
Agilent 2100 bioanalyzer (Agilent Technologies Palo Alto, CA) utilizing DNA 1000 
LabChip® kit following the manufacture’s instructions. The ratio of efflux 
pumps/house keeping gene was determined by dividing the concentration of target 
gene to that of 16SrRNA. The target/ house keeping gene ratio was assumed to be the 
relative expression level of efflux pump genes in bacteria (239). RT-PCR was 
repeated three times and the mean expression levels of certain efflux pump in 
different level fluoroquinolone-resistant Salmonella mutants were compared using 
SAS CONTRASTS statements. The P <0.01 was considered as significant difference.
Deletion of efflux pump genes in Salmonella The deletion of efflux pump genes from 
Salmonella was done by one step PCR gene knockout technique described by Datsenko K. A. et 
(49) (Fig 5-1). Briefly, PCR primer sets A (Table 5-2) were 
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Table 5-2, Oligonucleotide for efflux RT-PCR, gyrase, topoisomerase IV and regulatory gene 























Oligonucleotide for gyrase, topoisomerase and regulatory gene amplification
gyrA  ACGTATTGGGCAATGACTGG GGAGTCGCCGTCAATAGAAC































































































Figure 5-1.  A simple four-step gene deletion strategy. H1 and H2 refer to the 
homology extensions or regions. P1 and P2 refer to priming sites (49).
Figure 5-2.  Red recombinase expression plasmids. pKD20 and pKD46 (not shown) 
include 1,894 nt (31348–33241) and 2,154 nt (31088–33241) of phage λ (GenBank 
accession no. J02459), respectively (49).
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designed to amplify the FRT (Flp recognition target)-flanked resistance gene (KmR) 
from template plasmid pKD46.  The Primers A and B were composed of 3' 20bp
sequence homologous to the KmR gene, and 44bp 5’ extensions, which were 
homologous to the nearby genes at both sides of the target gene. Electrocompetent 
cells were prepared from Salmonella S.Py1 strain by concentrating 100-fold of mid-
log culture and washing three times with ice-cold 10% glycerol and transformed with 
Red helper plasmid pKD20 (Fig 5-2). Transformants carrying a Red helper plasmid 
was made electrocompetent cell again. PCR products, which contain a kanamycin 
resistance gene (KmR), FRT site, and homologous segments of nearby genes, were 
gel-purified, digested with DpnI, repurified, and suspended in elution buffer (10 mM 
Tris, pH 8.0). Electroporation was done by using a Micropulser electroporator (Bio-
Rad Hercules, CA) and 0.1-cm chambers according to the manufacturer's instructions 
using 40 µl of cells and 10–100 ng (2µl) PCR product. Shocked cells were added to 1-
ml SOC, incubated 1 h at 37°C, and then one-half was spread onto agar plates to 
select CmR or KmR transformants. After primary selection, mutants were maintained 
on medium without an antibiotic. They were colony-purified once nonselectively at 
37°C because the helper plasmid pKD20 is a temperature sensitive plasmid. The 
colony was tested for ampicillin sensitivity to test for loss of helper plasmid. 
PCR assays were used to verify the correct deletion of target gene in Salmonella 
chromosome. Several freshly isolated colonies were suspended in 100-µl water and 
heated for 10min at 100°C. Five-µl portions were used in 50-µl PCRs as described 
previously. Common test primers include: K1, K2 inside KmR and two nearby locus-
specific primer sets B (table 5-2), which targeted to both of the nearby genes of the 
target gene.  Three PCR reactions were used to verify the correct deletion using 
forward B and K1, K2 and reverse B, primer set B. 
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Phage transduction mediated by P22/H105 was used to conduct similar mutations 
in other level mutants and field strains as described in bacterial laboratory manual. 
The deletion was verified to be correct by three PCR reactions using forward B and 
K1, K2 and reverse B, and primer set B as described previously. In addition, the 
primers, which are specific to the individual efflux pump gene (Table 5-2) were used 
to test the loss of efflux pump gene in deletion mutants. 
Determination of drug target and efflux pump regulatory gene mutations in 
Salmonella mutants Amplifications of gyrA, gyrB, parC, parE, marR and 
acrR were performed using primers listed in Table 5-2. PCR was performed in 50µl 
distilled water with 0.25mM dNTP, 1.5mM MgCl2, 0.2u Tag enzyme and 50pmol 
each primer. DNA fragments gyrA, gyrB, parC and parE were amplified by using the 
following temperature profiles: incubating at 95 ºC for 10min; 90ºC 30s, 55ºC 45s and 
72ºC 45s for 30 cycles, and one final cycle of 72ºC for 7min. 
Predicted polypeptide products were analyzed for amino acid changes by 
comparison with wild type gyrA (#AE008801), gyrB  (AE008878 ), parC 
(#AE008846), parE (#AE008846) , marR (AE008766) and acrR (AE008717) and 
amino acid of these genes. 
Replacement of mutated gyrA and parC with wild type alleles in chromosome
In order to identify the role of gyrA and parC mutations on fluoroquinolone 
resistance in Salmonella, the gyrA and parC of fluoroquinolone-resistant mutants 
were replaced with their wild type alleles. The basic strategy of gene replacement is to 
insert an antimicrobial selective marker upstream of wild type gyrA gene in the 
bacterial chromosome. The DNA fragment containing wild type gyrA  gene and a 
selective marker along with flanking DNA was packed in phage P22 and transformed 
into recipient mutant cell to replace the mutated gyrA gene by homologous 
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Fig 5-3. The procedure for gene replacement. A kanamycin resistance gene was 
inserted into upstream of a wild type gyrA+ gene. The DNA fragment containing wild 
type gyrA and selective marker was transferred to fluroquinolone-resistant Salmonella
with mutations in gyrA through phage transduction. The wild type gyrA+ will replace 










recombination (Fig 5-3). Briefly, Primer set A1 and B1 were designed to PCR amplify
the FRT -flanked KmR from template plasmid pKD46.  Each primer A1 and B1 were 
composed of 3' 20bp, which were targeted to the KmR gene, and 40bp 5’ extensions, 
which was homologous to the upstream sequences of gyrA or parC genes. These two 
40bp extension sequences of primers A1 and B1 were homologous to the 80bp 
sequence in the upstream of gyrA or parC gene. PCR products amplified using these 
primers were transformed to Salmonella S.py1 strain containing the Red helper 
plasmid. The transformants were selected on knanmycine plates and purified as 
previously described. The replacement of gyrA or parC of fluoroquinolone-resistant 
Salmonella with wild type gyrA or parC gene by Salmonella S.Py1  was conducted by 
phage transduction as before. The replacement of mutated gyrA or parC with wild 
type allele was confirmed by sequencing the QRDR of gyrA and parC. 
Antimicrobial susceptibility testing All Salmonella strains including S21, 
S.py1, Salmonella field strains CS1, 3, 9, CHS 14, 18, 38 , induction mutants, deletion 
mutants, and gyrA or parC replacement mutants of these strains were assayed for the 
susceptibility to antimicrobial agents including cefoxitin, ceftiofur, ceftriaxone, 
cephalothin, amoxicillin-clavulanic, ampicillin, sulfamethoxazole, trimethoprime, 
ciprofloxacin, difloxacin, enrofloxacin, levofloxacin, gatifloxacin, nalidixic acid, 
orbifloxacin, sarafloxacin, danafloxacin, choramphenicol, gentamycin, streptomycin, 
amikacin, tetracycline. Minimal inhibitory concentrations were determined by the 
broth-microdilution method with the use of Sentitre system (Trek Diagnostic Systems, 
Westlake, Ohio). The seventeen antimicrobial agents used and their recommended 
resistance breakpoints are presented in Table 1. The strains were also assayed for the 
susceptibility to fluoroquinolones using fluoroquinolone sensititre system (Trek 
Diagnostic Syatem, Westlake, Ohio). The susceptibility to ciprofloxacin was also 
131
determined by the use of agar dilution method to cover high concentration of 
ciprofloxacin. The dilution range of ciprofloxacin agar dilution method was from 
0.0075µg/ml to128 ug/ml. All testing followed guidelines set forth by the National 
Committee Clinical Laboratory Standards (NCCLS) (90, 238). Escherichia coli
ATCC 25922, 35218, Enterococcus faecalis ATCC 29212, Staphylococcus aureus




Efflux pump gene expression level and deletion of efflux pump genes Salmonella
S.py1, S21 and their induction mutants (table 5-3), which showed different 
susceptibility to ciprofloxacin and nalidixic acid were screened for the expression of 
12 efflux pumps and two regulatory genes (table 5-3). Independent of genetic 
background, the efflux pump genes showed higher level of expression after the 
induction of Salmonella isolates to be resistant to fluoroquinolones. However, the 
increase of the expression of individual efflux pump genes  in S.py1 and S21 was 
different from each other. In S21, the expression level of mdl, acrE and acrF, which 
were undetectable in wild type, was significantly increased in S21-3 and S21-4 
mutants (P<0.01) (Fig 5-4 A). The expression level of acrA, acrB, and tolC, marA, 
emrA and emrB were significantly, consistently increased from S21 to S21-4 
(P<0.01). The expression level of yegO, yegN, and emrD which were undetectable in 
S21, S21-1, and S21-2 showed, although in low level, significantly increased in S21-3 
and S21-4 (P<0.01). Nearly no difference of ydhE expression was detected in all level 
mutants (Fig. 5-4 A). In Spy1, the expression of all efflux pump genes could be 
detected. Similar as S21, the expression level of acrE, acrF was significantly
increased in S. py1-3 and S. py1-4, and the expression level of acrA, acrB, tolC, emrA
and emrB were significantly, consistently increased form S.py1 to S.py1-4 (P<0.01). 
In contrast to S21, the expression level of mdlB didn’t not show significantly 
increased in S.py1-3 and S.py1-4. The marA, soxS and ydhE efflux pump genes did 
not show significantly overexpressed. (Fig 5-4 B). 
In order to further characterize the function of efflux pump on fluoroquinolone 
resistance in Salmonella, efflux pumps which showed increased expression with the 
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Table 5-3. Quinolone MICs of different fluoroquinolone-resistant Salmonella








GyrA GyrB ParC ParE marR acrR
S21 <4 <0.0015 -* - - - - - 
S21-1 64 0.5 S83F - - - - -
S21-2 >256 4 S83F - - - - -
S21-3 >256 32 S83F - - - - -
S21-4 >256 256 S83F - - - - -
S.py1 <4 <0.0015 - - - - - -
S.py1-1 64 0.5 S87Y - - - - -
S.py1-2 >256 4 S87Y - S80I - - -
S.py1-3 >256 32 S87Y - S80I- - - -












- S80I - - -
CHS14 128 0.12 S87G - - - - -
CHS18 256 0.12 S83F - - - - -
CHS38 32 0.06 S87G - - - - -
* No mutations
134





















Fig 5-4 (A). Expression level of different efflux pump and regulatory genes in Salmonella S21 and its fluoroquinolone-resistant 
mutants 
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Fig 5-4 (B). Expression level different efflux pump and regulatory genes in Salmonella S.py1 and its fluoroquinolone-resistant mutants
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increase of resistance to ciprofloxacin were deleted as previously described. 
Contiguous MDR efflux pump genes oriented in the same direction can constitute a
multidrug efflux operon. We choose to delete the contiguous MDR pump genes, 
which might associate to form the same MDR efflux pump system. Therefore, six 
unique deletions representing 12 individual genes were made in Salmonella S.py1, 
S21 and their mutants using the gene knockout technique and phage transduction 
technique described previously. Firstly, each of the deletions was conducted in 
Salmonella S.py1 strain. All deletions were verified as correct by analyzing the 
chromosomal locus by PCR amplification using the common verification primers 
forward B and K1, K2 and reverse B, B primer set. The deletions were termed 
acrAB::Kan, tolC::Kan, acrEF::Kan, yegMNO::Kan, emrAB::Kan, mdlAB::Kan. The 
deletion of efflux pump genes of S21, all level mutants of S21 and S.py1, and 
ciprofloxacin-resistant and nalidixic acid-resistant field strains were done by phage 
P22/H105 transduction as described in Materials and Methods. All transductants were 
confirmed to be lysogens by testing their sensitivity to phage H5. A further PCR assay 
was used to test the loss of the deleted gene. All the strains without deletion had the 
amplification with the same size as predicted, while no amplification was shown in 
deletion strains, providing that the deletion of efflux pump by phage transduction was 
successful. 
Target mutations and replacement The mutations in GyrA, GyrB, 
ParC, and ParE of S.py1, S21, and their fluoroquinolone resistance mutants were 
investigated. No mutations were detected in the QRDR of gyrA, gyrB, parC, parE
genes of wild type strains S.py1 and S21 (table 5-3). Different topoisomerase gene 
mutations were detected in the mutants of S.py1 and S21 after induction with 
cirofloxacin. A single GyrA mutation with the substitution of S83F was detected in all 
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fluoroquinolone resistance mutants of S21. No mutations in GyrB, ParC and ParE
were detected in those mutants. In contrast to S21, in addition to a single mutation 
with the substitution of S87Y was present in all fluoroquinolone resistance mutants of 
S.py1, a single S80I mutation in ParC was detected in S.py1-2, S.py1-3, and S.py1-4 . 
No mutations were detected in GyrB and ParE in all fluoroquinolone resistance 
mutants of S.py1 (table 5-3). The topoisomerase gene mutations were also detected in 
fluoroquinolone-resistant field strains. Double GyrA mutations, S83D and S87Y, and 
single ParC mutation, S80I, were detected in CS1, CS3, and CS9 which were resistant 
to ciprofloxacin. Different single GyrA mutation, S87G, S83F and S87G, were found 
in CH14, CH18 and CH38 respectively. No mutations in GyrA, ParE, MarR and AcrR
genes were detected (Table 5-3).  
The construction of Salmonella S.py1 mutants by insertion of KmR-FRT 
upstream of gyrA and parC gene was performed as described above. A KmR with 
FRT flanking sequence was successfully inserted into upstream of gyrA or parC of 
Salmonella S.py1. The replacement of mutated gyrA and parC in fluroquinolone-
resistant mutants and field strains with wild type alleles from Salmonella S.py1 was 
performed by phage transduction as described above. Each of the four 
fluoroquinolone-resistant mutants of Salmonella S21 and S.py1 and six of the field 
strains, which showed mutation in gyrA gene was replaced with wild type gyrA allele 
from S.py1. The replacement mutants were confirmed to be lysogens and further 
confirmed by sequencing the QRDR of the gyrA gene. All the strains with gyrA gene 
replacement failed to show any mutation in the QRDR of their gyrA gene. The wild 
type parC allele from Salmonella S.py1 was used to replace the mutated parC in 
S.py1-2, S.py1-3, S.py1-4 and three field strains CS1, CS3, CS9 as done in gyrA
replacement. 
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Antimicrobial susceptibility testing results All Salmonella strains including 
S21, S.py1, Salmonella field strains CS1, 3, 9, CHS 14, 18, 38, induction mutants, 
deletion mutants, and gyrA/parC replacement mutants of these strains (table 5-4) were 
assayed for their susceptibility to 24 different antimicrobials, as described in Materials 
and Methods. The exposure of Salmonella S21 to different concentrations of 
ciprofloxacin caused the strain resistant to not only fluoroquinolone but also other 
classes of drugs including tetracycline, chloramphenicol, trimethoprim, and ß-lactam. 
First level mutant S21-1 was resistant to nalidixic acid as well as tetracycline, 
chloramphenicol, and ampicillin. In addition to the resistance to these drug, S21-2 and 
upper level mutants were resistant to cephalothin and cefoxitin and showed moderate
resistance to amoxicillin-clauvulanic (MIC=16/8µg/ml) and ceftiofur (MIC=4 µg/ml). 
The MIC to ceftriaxone, gentamycin, and amikacin didn’t change in all level mutants. 
The change of MIC to sulfamethoxazole and streptomycin couldn’t be addressed 
because S21 was resistant to these two drugs. Similar to S21, the induction of S.py1 
with ciprofloxacin changed the susceptibility to previously described drugs.  All level 
mutants of S.py1 acquired resistance to chloramphenicol, cefoxitin and cephalothin. 
However, the mutants only showed moderate resistance to tetracycline, ampicillin, 
and ceftiofur. The MIC to trimethoprim only increased four fold. No change was 
detected in other drugs including streptomycin. 
The acrAB or tolC deletion mutants dramatically decreased the MIC of 
fluoroquinolone as well as other classes of drugs. Deletion of acrAB or tolC of wild 
type strains S21 and S.py1 made these two strains to be hypersusceptible to 
fluoroquinolones (MIC < 0.015µg/ml) and other class of drugs including 
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Table 5-4. Antimicrobial susceptibility of deletion and replacement mutants of Salmonella S21
ID GAT SAR ENR CIP DIF DAN LEV ORB NAL FOX CHL TET AMO TIO COT CEP KAN AMP
S21 0.03 0.03 0.06 <0.015 0.25 0.03 0.03 0.12 4 4 8 <4 <1/05 0.5 0.25/4.75 <2 <8 2
S21 
tolC::Kan
<0.015 <0.015 <0.015 <0.015 <0.015 <0.015 <0.015 <0.015 1 1 <2 <4 <1/0.5 <0.12 <0.12/2.38 <2 >64 <1
S21 
acrAB::Kan
<0.015 <0.015 <0.015 <0.015 <0.015 <0.015 <0.015 <0.015 1 1 <2 <4 <1/0.5 <0.12 <0.12/2.38 <2 >64 <1
S21gyrA+ 0.03 0.03 0.06 <0.015 0.25 0.03 0.03 0.12 4 4 8 <4 <1/05 0.5 0.25/4.75 <2 >64 2
S21parC+ 0.03 0.03 0.06 <0.015 0.25 0.03 0.03 0.12 4 4 8 <4 <1/05 0.5 0.25/4.75 <2 >64 2
S21-1 0.5 1 0.5 0.25 4 0.5 0.5 2 256 2 >32 32 16/8 0.5 0.25/4.75 8 <8 >32
S21-
1tolC::Kan
0.03 0.12 0.06 0.06 0.25 0.06 0.06 0.12 32 1 <2 <4 16/8 <0.12 <0.12/2.38 <2 >64 >32
S21-1 
acrAB::Kan
0.03 0.12 0.06 0.06 0.25 0.06 0.06 0.12 32 1 <2 <4 16/8 <0.12 <0.12/2.38 <2 >64 >32
S21-1 gyrA+ 0.03 0.03 0.06 0.015 0.25 0.03 0.03 0.12 4 8 >32 >32 4/2 1 0.25/4.75 8 >64 >32
S21-1parC+ 0.5 1 0.5 0.25 4 0.5 0.5 2 256 2 >32 32 16/8 0.5 0.25/4.75 8 >64 >32
S21-2 1 8 8 4 >16 4 1 16 >256 >16 >32 >32 16/8 4 2/38 >32 <8 >32
S21-
2tolC::Kan
0.06 0.5 0.12 0.12 0.25 0.12 0.06 0.25 64 2 <2 <4 16/8 <0.12 <0.12/2.38 8 >64 >32
S21- 2 
acrAB::Kan
0.06 0.5 0.12 0.12 0.25 0.12 0.12 0.25 64 2 <2 <4 16/8 <0.12 <0.12/2.38 8 >64 >32
S21-2gyrA+ 0.25 0.25 1 0.25 2 1 0.25 2 64 >16 >32 >32 8/4 4 >4/76 32 >64 >32
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S21-2parC+ 1 8 8 4 >16 4 1 16 >256 >16 >32 >32 16/8 2 >4/76 32 >64 >32
S21-3 8 >16 >16 32 >16 >16 >16 16 >256 >16 >32 >32 16/8 4 >4/76 >32 <8 >32
S21-
3tolC::Kan
0.06 0.5 0.12 0.25 0.5 0.25 0.12 0.5 32 1 <2 <4 16/8 <0.12 <0.12/2.38 8 >64 >32
S21-3 
acrAB::Kan
0.06 0.5 0.25 0.25 1 0.25 0.12 0.5 64 1 <2 <4 16/8 <0.12 <0.12/2.38 8 >64 >32
S21-3gyrA+ 1 1 2 1 4 2 1 2 >256 >16 >32 >32 8/4 2 >4/76 >32 >64 >32
S21-3parC+ 16 >16 >16 32 >16 >16 16 >16 >256 >16 >32 >32 8/4 4 >4/76 32 >64 >32
S21-4 16 >16 >16 256 >16 >16 >16 16 >256 >16 >32 >32 16/8 4 >4/76 >32 <8 >32
S21-4 
tol::KanC
0.25 1 0.5 0.5 4 0.5 0.5 1 128 2 32 8 16/8 <0.12 <0.12/2.38 8 >64 >32
S21-4 
acrAB::Kan
0.06 0.5 0.12 0.25 1 0.25 0.25 0.12 64 1 <2 <4 16/8 <0.12 <0.12/2.38 8 >64 >32
S21-4gyrA+ 2 2 4 2 4 2 2 8 128 >16 >32 >32 8/4 2 >4/76 >32 >64 >32
S21-4parC+ 16 >16 >16 128 >16 >16 16 >16 >256 >16 >32 >32 8/4 4 >4/76 32 >64 >32
GAT, Gatifloxacin; SAR, Sarafloxacin; ENR, Enrofloxacin; CIP, Ciprofloxacin; DIF, Difloxacin; DAN, Danofloxacin; LEV, Levofloxacin; 
ORB, Orbifloxacin, NAL, Nalidixic Acid, FOX, Cefoxitin; CHL, Choramphenicol; TET, Tetracyclin; AMO, Amoxicillin-clavulanic; TIO, 
Ceftiofur; COT, Trimethoprim-sulfamethoxazole; CEP, Cephalothin; KAN, Kanamycin; AMP, Ampicillin.
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Table 5-5. Antimicrobial susceptibility of deletion and replacement mutants of Salmonella field strains
ID GAT SAR ENR CIP DIF DAN LEV ORB NAL FOX CHL TET AMO TIO COT CEP KAN AMP
CS1 4 16 16 16 >16 >16 8 >16 >256 1 >32 >32 32/16 1 >4/76 16 <8 >32
CS1tolC;;Kan 0.5 4 4 2 4 4 1 4 256 1 >32 32 32/16 0.5 2/38 8 >64 >32
CS1acrAB::Kan 0.5 4 4 4 16 4 2 4 >256 1 >32 >32 32/16 0.5 2/38 8 >64 >32
CS1parC+ 8 >16 >16 16 >16 >16 8 >16 >256 1 >32 >32 32/16 1 >4/76 16 >64 >32
CS1gyrA+ 0.06 0.06 0.06 0.03 0.5 0.06 0.06 0.25 4 2 >32 >32 32/16 1 >4/76 8 >64 >32
CS3 4 16 16 16 >16 >16 8 >16 >256 1 >32 >32 32/16 1 >4/76 16 <8 >32
CS3tolC::Kan 1 4 2 2 4 4 1 4 256 1 >32 32 32/16 0.5 2/38 8 >64 >32
CS3acrAB::Kan 0.5 4 4 4 4 4 1 4 >256 1 >32 >32 32/16 0.5 2/38 8 >64 >32
CS3parC+ 4 16 16 16 >16 >16 8 >16 >256 1 >32 >32 32/16 1 >4/76 16 >64 >32
CS3gyrA+ 0.06 0.06 0.06 0.03 0.25 0.06 0.06 0.12 4 2 >32 >32 32/16 1 >4/76 8 >64 >32
CS9 8 >16 >16 16 >16 >16 8 >16 >256 1 >32 >32 32/16 1 >4/76 16 <8 >32
CS9tolC;;Kan 0.5 4 4 2 4 4 1 >16 256 1 >32 32 32/16 0.5 2/38 8 >64 >32
CS9acrAB::Kan 0.5 4 4 2 8 4 1 4 256 1 >32 >32 32/16 0.5 2/38 8 >64 >32
CS9parC+ 8 >16 >16 16 >16 >16 8 >16 >256 1 >32 >32 32/16 1 >4/76 16 >64 >32
CS9gyrA+ 0.03 0.03 0.06 0.03 0.25 0.06 0.06 0.12 4 2 >32 >32 32/16 1 >4/76 8 >64 >32































CHS14gyrA+ 0.03 0.03 0.06
<0.01
5
0.5 0.03 0.06 0.12 4 2 8 >32 2/1 1 0.25/4.75 <2 >64 <1
CHS18 0.25 0.25 0.5 0.12 2 0.5 0.25 1 256 2 8 4 1/0.5 1 0.12/2.38 4 8 2
CHS18tolC::Ka
n
0.03 0.03 0.03 0.03 0.06 0.06 0.03 0.06 32 1 2 4 1/0.5 0.12 0.12/2.38 2 >64 1
CHS18acrAB::
Kan
0.12 0.03 0.25 0.03 1 0.03 0.03 0.5 16 1 2 4 1/0.5 0.12 0.12/2.38 2 >64 1
CHS18gyrA+ 0.06 0.06 0.12 0.06 0.25 0.06 0.06 0.12 32 2 4 4 1/0.5 1 0.12/2.38 4 >64 2










<0.015 <0.015 <0.015 <0.15 0.5 0.5 4 16 1/0.5 0.12 >4/76 8 >64 >32
CHS38acrAB::
Kan








<0.015 <0.015 <0.015 <0.15 8 4 32 32 1/0.5 0.5 >4/76 16 >64 >32
GAT, Gatifloxacin; SAR, Sarafloxacin; ENR, Enrofloxacin; CIP, Ciprofloxacin; DIF, Difloxacin; DAN, Danofloxacin; LEV, Levofloxacin; 
ORB, Orbifloxacin, NAL, Nalidixic Acid, FOX, Cefoxitin; CHL, Choramphenicol; TET, Tetracyclin; AMO, Amoxicillin-clavulanic; TIO, 
Ceftiofur; COT, Trimethoprim-sulfamethoxazole; CEP, Cephalothin; KAN, Kanamycin; AMP, Ampicillin.
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chloramphenicol, tetracycline, trimethoprim, ampicillin, cefoxitin, and ß-lactam (Table 5-
4). The ciprofloxacin MIC reduced up to 11 log2 dilutions when the acrAB or tolC was 
deleted in these mutants of S21 and Spy1. All deletion mutants for acrAB and tolC
became susceptible to all fluoroquinolones. High level fluoroquinolone resistance 
mutants remained, although lower MIC than breakpoint, higher MIC after the deletion of 
acrAB or tolC in these mutants (Table 5-4). The deletion of acrAB and tolC made all 
mutants more susceptible than wild type to chloramphenicol, tetracycline, ceftioufur, 
cefoxitin, amoxicillin/clavulance, trimethoprim/sulfamethoxazol. However, acrAB or
tolC deletion mutants of S21-2, S21-3, and S21-4 remained resistant to ampicillin 
(MIC>32µg/ml) and cephalothin (MIC=8µg/ml) (Table 5-4). It is suggested that efflux 
pumps other than acrAB-tolC, which was induced by fluoroquinolone, accounted for the 
resistance to ampicillin and decreased susceptibility to cephalothin. The deletion of 
acrEF, emrAB, mdlAB, yegMNO in S21, S.py1, and ifluoroquinolone resistance mutants 
didn’t affect the MIC to any antimicrobials other than fluoroquinolones tested (table 5-4). 
The replacement of mutated gyrA/parC with wild type alleles in S21 and S.py1 didn't 
change the susceptibility to any antimicobials other than fluoroquinolones tested. 
However, replacement of mutated gyrA with its wild type allele gyrA+ reduced the 
fluoroquinolone MICs of fluoroquinolone resistance mutants up to eight log2 dilutions, 
while not to other antimicrobial MICs. High level fluoroquinolone resistance mutants
remained, although lower MIC than breakpoint, higher MIC after the replacement of 
mutated gyrA with its wild type allele gyrA+ in these mutants (Table 5-4). Replacement 
of mutated parC with its wild type allele in fluoroquinolone resistance mutants of S.Py1 
didn’t affect the susceptibility to any of the drugs tested. 
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The mechanisms of fluoroquinolone resistance in Salmonella field strains were 
similar to what was found in the laboratory-induced strains. The deletion of acrAB or 
tolC or replacement with a wild type gyrA allele in field strains significantly reduced
fluoruoquinolone MICs (Table 5-5). The deletion of acrAB and tolC in field strains CS1, 
CS3, and CS9 did not reduced fluoroquinolone MICs to a level as low as in laboratory 
induced strains. For instance, S21-2 and CS1, CS3, CS9 have same ciprofloxacin MIC of 
8µg/ml. The deletion of acrAB and tolC in S21-2 reduced the ciprofloxacin MIC to 
0.06µg/m, while deletion of acrAB and tolC in CS1, CS3, CS9 reduced the ciprofloxacin 
MIC to 0.5µg/ml. Replacement of mutated gyrA of CS1, CS3, and CS9 with wild type 
allele gyrA+ reduced fluoroquinolone MIC to lower level than in laboratory induced 
mutants. For instance, replacement of mutated gyrA with wild type allele in S21-2 
reduced ciprofloxacin MIC to 0.25µg/ml, while replacement of mutated gyrA with wild 
type allele in CS1, CS3, CS9 reduced the ciprofloxacin to 0.03µg/ml. Deletion of acrAB
or tolC or replacement of gyrA of CHS14, CHS18, and CHS38 with wild type allele 
reduced the MIC to a very low level. In contrast to laboratory-induced mutants, the 
deletion of acrAB or tolC of CS1, CS3, and CS9 failed to reduce chloramphenicol, 
tetracycline, and ß-lactam MIC. The maintenance of the resistance to these drugs was due 
to the presence of other mechanisms of resistance in these strains. These strains were 
detected to contain the cat1 and cat2 genes conferring resistance to chloramphenicol; the 
tetB and tetA genes conferring resistance to tetracycline; a dhfrI gene conferring 
resistance to trimethoprim; and a blaOXA1 conferring resistance to ampicillin and showing
decreased susceptibility to cephalothin and cefoxitin. The maintenance of tetracycline 
resistance in CH14 and tetracycline, trimethoprim and ampicillin resistance in CH38 
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strains was due to the presence of tetA gene in both strains and blaTEM-1 and dhfrI in 
CHS38. Like laboratory-induced strains, the deletion of acrEF, emrAB, mdlAB, yegMNO
in these field strains failed to change MIC of all drugs tested. The replacement of parC
gene in CS1, CS3, and CS9 failed to reduce the MIC of all drugs tested. 
Discussion
The mechanism of nalidixic acid resistance in Salmonella has been attributed to a 
single mutation in the gyrA gene, leading to an amino acid substitution either at position 
83 or 87.  These Salmonella strains were nalidixic acid-resistant and showed decreased 
susceptibility to fluoroquinolone. In high-level fluoroquinolone-resistant Salmonella, 
double mutations leading to an amino acid substitution in both of the 83 and 87 positions
were detected in the gyrA gene. No mutations in parC gene were detected in high level 
fluoroquinolone-resistant Salmonella until recently. A substitution at position Ser80 in 
parC has been reported in animal and human isolates. The role of target gene mutations 
in quinolone resistance has been studied in E. coli by introducing the mutation 
experimentally in the absence of quinolone selection. Introducing a single gyrA S83 or 
S87 mutation, double gyrA mutations, or single parC S80 didn’t result in ciprofloxacin 
resistance (MIC<4µg/ml). However, the combination of three mutations (gyrA S83, D87, 
and parC S80) was associated with higher MIC of CIP (>64 µg/ml)(12). In addition, the 
introducing a plasmid-coded allele of gyrA+ or parC+ respectively reduced the MICs of 
ciprofloxacin, which indicted that both types of mutations contributed to the expression 
of quinolone resistance (84, 105). The role of gryA or parC mutations on fluoroquinolone 
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resistance in Salmonella is different from that in E. coli. In this study, parC mutation was 
detected in S.py1-2, S.py1-3, S.py1-4, while no parC mutation was detected all mutants 
of S21. Independent of parC mutation, the replacement of gyrA S83, S87 or the 
combination of these two mutations with wild type gyrA allele significantly reduced 
fluoroquinolone MICs in both laboratory-induced mutants and field strains. The 
replacement of mutated parC with wild type allele in S.py1 mutants and field strains 
failed to reduce fluoroquinolone MICs in these strains. No mutation was detected in gyrB
and parE in induction mutants of S21 and S.py1. Although mutation in Salmonella gyrB 
was reported (80, 112), it is suggested that the gyrB and parE in Salmonella were not 
associated with fluoroquinolone resistance. It was concluded that mutation in gyrA while 
not the mutation in other topoisamerase genes was associated with fluoroquinolone 
resistance in Salmonella. 
Our results are consistent with the phenomenon of gyrA and parC mutations in 
fluoroquinolone resistance Salmonella. The gyrA mutation is always detected in 
fluoroquinolone-resistant Salmonella, while the parC mutation is not always associated 
with high level fluoruoquinolone resistance in Salmonella and only reported recently. The 
inconsistency between the parC mutation and fluoroquinolone resistance in Salmonella
may indicated that Salmonella parC was not a secondly target of fluoroquinolone. In 
contrast to Salmonella, the parC mutation in E. coli is always detected in high level 
fluoroquinolone-resistance E. coli and was suggested as secondly target of 
fluoroquinolone (84). The E. coli parC as a secondly target of fluoroquinolone was 
supported by testing the role of parC mutation in fluoroquinolone-resistant E. coli. The 
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introducing of wild type parC into fluoroqinolone-resistant E. coli reduced the 
fluoroquinolone MICs in this E coli strain.
Our study disagreed with a recent report of the role of parC mutation in 
fluoroquinolone-resistant Salmonella (80). The difference between these two studies 
might be due to the use of deficient methods in their study. First, in their study, a wild 
type parC gene from E. coli while not from Salmonella carried by a high copy cloning 
vector was transformed into fluoroquinolone-resistant Salmonella. The dominance of E. 
coli parC gene in Salmonella can not address of the role of Salmonella parC mutation in 
fluoroquinolone resistance. Second, the dominance test which lacked the power to 
directly identify the role of topoisomerase gene mutations on fluoroquinolone resistance
was used in their study to address the role of target mutation on fluoroquinolone 
resistance. In this study, we directly replace the mutated parC of Salmonella with wild 
type allele in bacterial chromosome. The results from our study directly demonstrate the 
role of topoisomerase gene mutation in fluoroquinolone resistance in bacteria. Our 
methodology is extremely useful in the study of the role of gene mutations on 
fluoroquinolone resistance in Salmonella, E. coli or other Gram-positive or Gram-
negative organisms. 
Efflux pump is a known mechanism of antimicrobial resistance. Among more than 
20 multiple drug resistant efflux pumps studied in E. coli, at least three representing 
acrAB, yegMON, norm are associated with fluoroquinolone resistance (148, 241). acrAB
appears to affect fluoroquinolone susceptibility most significantly (148, 196, 241). The 
deletion of acrAB in E. coli including strains with target gene mutations, resulted in 
fluoroquinolone hypersusceptibility (MIC<0.06µg/ml) and increased susceptibility to 
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other classes of drugs (196, 241). In order to examine the role of efflux pumps in 
fluoroquinolone resistance in Salmonella, RT-PCR was first used to screen for the 
overexpessed efflux pump gene in fluoroquinolone-resistant Salmonella strains. The 
expression level of several efflux pumps is consistently increased according to the 
decrease of the susceptibility to fluoroquinolone. However, some efflux pumps such as 
MdlB, which was dramatically overexpressed in high level mutants of S21, was not 
significantly changed in mutants of S.py1. It is suggested that different systems might be 
stimulated in these two isolates to respond to the fluoroquinolone selection pressure. In 
our study, only acrAB was associated with the fluoroquinolone resistance in Salmonella. 
Deletion of acrAB in all Salmonella strains dramatically increased the susceptibility to 
fluoroquinolone, while deletion of acrEF, emrAB, yegMNO, mdlAB had no effect. 
Overexpression of these efflux pumps in Salmonella may be due to the overexpression of 
some regulatory gene such as marA and soxS, whose overexpression can lead to the 
overexpression of acrAB and tolC. The overexpression of marA and soxS can also cause 
the overexpression of other efflux pump genes in Salmonella (169). Deletion of tolC
caused the same effect as deletion of acrAB in Salmonella, which agreed with the acrAB-
tolC efflux pump model (134). The key role of acrAB-tolC in fluoroquinolone resistance 
in Salmonella agreed with the resent report in which the deletion of acrAB in 
fluoroquinolone-resistant Salmonella enterica Typhimurium DT204 resulted in a 
fluoroquinolone susceptible phenotype for the ciprofloxacin (MIC=2µg/ml) (196). In 
contrast to fluoroquinolone-resistant efflux pumps in E. coli, the efflux pump YegMNO 
is not associated with fluoroquinolone resistance in Salmonella. Although the YdhE 
efflux pump is not further studied by gene deletion, the expression level of YdhE efflux 
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pump didn’t change in all level mutants suggesting that YdhE efflux pump might not be 
related to the fluoroquinolone resistance in Salmonella. 
In conclusion, gyrA mutation and upregulation of acrAB-tolC, are implicated in the 
fluoroquinolone resistance of Salmonella. Lower level expression of acrAB was
associated with bacterial survival in lower level fluoroquinolone. The deletion of acrAB
in Salmonella S.py1 and S21 made the cell hyperrsusceptible to fluoroquinolone 
(MIC<0.015µg/ml). Mutations in gyrA can confer bacteria resistant to quinolone 
(nalidixic acid) and showed decreased susceptibility to fluoroquinolone. The increased 
expression of acrAB-tolC, which can pump more and more fluoroquinolone out of 
bacteria plasma, can confer the bacteria to be resistant to higher level of fluoroquinolone. 
Independent of target gene mutation, the increased expression of acrAB-tolC  in different 
Salmonella mutants caused the bacteria to be resistant to higher and higher concentrations
of fluoroquinolone (ciprofloxacin MIC = 32 and 256 µg/ml). The highly fluoroquinolone 
resistance in Salmonella relied on the combination of these two mechanisms. The 
deletion of acrAB-tolC or replacement of mutated gyrA made the high level 
fluoroquinolone-resistant mutant (ciprofloxacin MIC = 256 µg/ml)) susceptible all 
fluoroquinolones tested. 
The difference of mechanisms of fluoroquinolone resistance between laboratory-
induced and field-selected fluoroquinolone-resistant Salmonella was the different roles 
the target gene mutation and efflux played in these Salmonella isolates. Overexpression 
of efflux pump played a major role in laboratory-induced fluoroquinolone-resistant 
Salmonella. Deletion of acrAB or tolC in S21-3 or S.py1-3 (ciprofloxacin MIC = 32 
µg/ml) reduced MIC to 0.25 µg/ml, while replacement mutated gyrA (single mutation 
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S87) with wild type allele reduced the MIC to 1 µg/ml. In contract to laboratory-induced 
strains, target mutations played major role in fluoroqunolone resistance in field 
Salmonella strains. Double mutations in gyrA (S83 or S87) were found in field selected 
fluoroquinolone-resistant Salmonella strains (ciprofloxacin MIC = 16 µg/ml). The 
replacement of mutated gyrA with wild type allele reduced the MIC to 0.03 µg/ml, while 
the deletion of acrAB or tolC only reduced the MIC to 4 µg/ml. It can be concluded that 
long-term low concentrations selection (field selection) tented to select more mutations in 
target gene which can confer higher level resistance than single target gene mutation and 
short term high concentrations of drugs tented to upregulate efflux expression which can 
confer high level resistance. 
Independent of target mutations, the high level fluoroquinolone-resistant mutants 
displayed higher level fluouroquinolone MICs after replacement of mutated target gene 
with wild type allele. It is easy to understand because the expression level of efflux pump 
increased in different level fluoroquinoloen-resistant mutants. The more efflux pump was 
expressed in high level fluoroquinolone mutants can maintain higher MIC when gyrA
mutation was converted to wild type allele. Independent of efflux pump, the high level 
fluoroquinolone-resistant mutants displayed higher fluoroquinolone MICs after the 
deletion of acrAB or tolC. It is suggested that this difference may due to the following 
reasons: 1) the overexpression of acrAB in Salmonella mutants was regulated by the 
overexpression of marA, which in turn decreased the expression of outer membrane 
protein ompF. The decreased expression of ompF would decrease the intake of 
fluoroquinolone to bacterial plasm. 2) some other efflux pumps, which can also be 
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induced by fluoroquinolone, can slightly effect the fluoroquinolone resistance in 
Salmonella. 
Understanding the mechanisms of fluoroquinolone resistance in Salmonella provide 
guidance in fluoroquinolone chemotherapy in the future. The combination use of 
fluoroquinolone and an efflux pump inhibitor, particularly the acrAB-tolC efflux pump 
inhibitor such as 7-nitro-8-methyl-4-[2'-(piperidino)ethyl]-aminoquinoline, could 1) make 
fluoroquinolone efficient to intermediate resistant or resistant Salmonella, 2) decrease the 
chance of target gene mutation, 3) prolong the serve life of fluoroquinolone drugs in the 
future (118, 173, 174).  However, the inhibition of acrAB-tolC might stimulate other 
backup systems (other efflux pumps) to confer resistance to fluoroquinolone (196). Such 
a strategy will require the development of a broad efflux pump inhibitor in the future. 
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Chapter 6 Summary
Bacterial antimicrobial resistance in both the medical and agricultural fields has 
become a serious problem worldwide. The use of antimicrobial agents in animals, 
particular use antimicrobial agents as prophylaxis and growth promoter, favors the 
selection of antimicrobial resistance in bacteria. These resistant bacteria may 
subsequently transmit to humans through food chain or human and animal interactions. 
The main thrust of this work was to characterize and explore the molecular mechanisms 
of antimicrobial resistance in foodborne pathogens.
Salmonella is a leading cause of foodborne illness in the United States. Each year, 
an estimated of 1.4 million cases of salmonellosis occour in the US which causes16,000 
hospitalization and 600 deaths. In recent years, the portion of Salmonella which are 
resistant to clinical important drugs such as ciprofloxacin and ceftriaxone are increasing. 
The emergence of resistance to front line drugs in Salmonella has caused public health 
consequence. The antimicrobial resistance phenotypes of Salmonella isolated from food 
samples were characterized in this study to evaluate the safety of food products because 
most of Salmonella infections resulted from the ingestion of contaminated meat products.  
Of the most important are the detection of ceftriaxone-resistant Salmonella from the US 
meat products and the fluoroquinolone-resistant Salmonella from Chinese meat products. 
Genotype characterization of these multiple antimicrobial-resistant Salmonella revealed 
that ß-lactamase gene blaCMY-2 was widely present in ceftriaxone-resistant Salmonella and 
conferred resistance to most of the ß-lactams tested. Most of the antimicrobial-resistant 
determinants were encoded in self-transmissible plasmid and can be transferred between
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different organisms. The class I integron also played an important role on transmission of 
antimicrobial resistance determinants in bacteria. 
Characterization of antimicrobial resistance genes is a powerful tool for 
describing bacterial pathogens. For instance, it can be used to investigate the 
population dynamics of clinical isolates, including the spatial and temporal distribution 
of resistance genes. The drawback of using PCR and similar assays to characterize the 
antimicrobial resistance genes, however, is that they are for the most part limited in the 
number of genes that can be reasonably screened. Microarray is a powerful tool to 
analyze hundreds and thousands of genes on a microchip and could be a good tool for 
characterization of antimicrobial resistance genes in bacteria. Testing of antimicrobial-
resistant and virulence genes from E. coli and Salmonella using DNA-based microarray 
demonstrated that Microarray analysis is an effective method to rapidly screen 
pathogenic strains of Salmonella and E. coli for multiple antimicrobial resistance and 
virulence genes. This method could also be useful to identify the potential 
antimicrobial resistance genes which failed to show any phenotype in bacteria but 
would be easily inducted under antibiotic selective pressure. 
Although the Salmonella isolates which were resistant to fluoruoquinolone were 
rare, the Salmonella that showed decreased susceptibility to fluoroquinolone are 
increasing. The emergence of fluoruoquinolone resistance in Salmonella caused 
significant public health consequence because fluoroquinolone is a choice in the 
treatment of Salmonella invasive infections in the US. It is important to study the 
molecular mechanisms of antimicrobial resistance particularly the resistance to front 
line drugs because the understanding of the molecular mechanisms by which 
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antimicrobial resistance emerges and spreads should enable us in the future to develop 
effective intervention strategies to reduce or stop its progression. Our work has shown 
that when Salmonella are exposed to fluoroquinolones, certain efflux pumps are 
overexpressed in tandem with particular mutations in topoisomerase genes (gyrA and 
parC).  Using deletion studies, it appears that the most relevant genes with regards to 
the selection of fluoroquinolone resistance phenotypes among Salmonella are the 
AcrAB efflux pump and the gyrA portion of DNA gyrase.  Understanding the 
mechanisms of fluoroquinolone resistance in Salmonella can give guidance in 
fluoroquinolone chemotherapy in the future. Combination use of fluoroquinolone and 
efflux pump inhibitor, particularly acrAB-tolC efflux pump inhibitor such as 7-nitro-8-
methyl-4-[2'-(piperidino)ethyl]-aminoquinoline, can 1) make fluoroquinolone efficient 
to intermediate resistant or resistant Salmonella, 2) decrease the chance of target gene 
mutation, 3) prolong the serve life of fluoroquinolone drugs in the future. 
Pathogenic bacteria, such as Salmonella, are not the only concern when considering 
antimicrobial resistance in bacteria with food animal reservoirs. Commensal bacteria, 
which are naturally occurring host flora, constitute an enormous potential reservoir of 
resistance genes for pathogenic bacteria. The prevalence of antibiotic resistance in the 
commensal bacteria of humans and animals is considered to be a good indicator of the 
selective pressure of antibiotic usage and reflects the potential for resistance in future 
infection. Characterization of E. coli isolates from diseased swine and chicken revealed 
that multiple-antimicrobial-resistant E. coli, including fluoroquinolone-resistant variants, 
are commonly present among diseased swine and chickens in China It was suggested the 
need for the introduction of surveillance programs in China to monitor antimicrobial 
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resistance in pathogenic bacteria that can be potentially transmitted to humans from food
animals.
In the future, we will keep monitoring the prevalence of the resistance to novel 
drugs in foodborne pathogens and to study the molecular mechanisms of these 
resistances. From our work, the efflux pumps played an important role in the resistance 
to many different antimicrobials. The study of efflux pump and antimicrobial resistance 
is another important aspect in this field. In the future, we will propose to develop a 
microarray which contains all membrane transporters of bacteria. This microarray 
could be used to screen for the associated efflux pump which can coffer resistance to 
different antimicrobials. This efflux pumps could be further characterized using the 
deletion and RNAi techniques. The doness of these studies may provide useful 
information on how to control the antimicrobial resistance in bacteria in the future. 
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